Processing 00000000.tx.1: New drugs for Alzheimer's disease and other dementias ROGER BULLOCK, MRCPsych Department of Old Age Psychiatry and Kingshill Research Centre, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon SNI 4HZ, UK. 

Phrase: "New drugs for Alzheimer's disease"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0013227:Drugs [Pharmacologic Substance]
   726 E C1254351:Drug [Pharmacologic Substance]

Phrase: "and"

Phrase: "other dementias ROGER BULLOCK,"

Phrase: "MRCPsych Department of Old Age Psychiatry"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   864   C0587497:Old age psychiatry department [Health Care Related Organization]
   783   C0587494:Psychiatry department [Health Care Related Organization]
   753   C1704729:Department [Organization]

Phrase: "and"

Phrase: "Kingshill Research Centre,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0683939:research center [Manufactured Object,Organization]
   827   C0205099:Center [Spatial Concept]

Phrase: "Avon"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454839:Avon [Geographic Area]

Phrase: "and"

Phrase: "Wiltshire Mental Health Trust,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0237935:Trust [Individual Behavior]
   812   C3245466:trust [Idea or Concept]

Phrase: "Victoria Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "Swindon SNI 4HZ,"

Phrase: "UK."
Processing 00000000.tx.2: Tel: +44 (0)1 793 437501; 

Phrase: "Tel"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0254343:TEL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C0796520:TEL [Gene or Genome]
  1000   C3272379:TEL [Intellectual Product]

Phrase: ":"

Phrase: "+44"

Phrase: "(0"

Phrase: ")"

Phrase: "1 793 437501"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C2827734:1+ [Quantitative Concept]
   827   C2981698:1+ [Classification]

Phrase: ";"
Processing 00000000.tx.3: Fax: +44 (0)1 793 437521 Correspondence: e-mail: roger.bullock{at}kingshill-research.org Declaration of interest R.B. has worked on clinical trials in dementia for all the major pharmaceutical companies. 

Phrase: "Fax"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085205:Fax [Manufactured Object]
  1000   C1549619:FAX [Conceptual Entity]
  1000   C1880669:Fax [Manufactured Object]

Phrase: ":"

Phrase: "+44"

Phrase: "(0"

Phrase: ")"

Phrase: "1 793 437521 Correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0282413:Correspondence [Intellectual Product]

Phrase: ":"

Phrase: "e-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "roger.bullock{at}kingshill-research.org Declaration"

Phrase: "of interest R.B."

Phrase: "has"

Phrase: "worked on clinical trials"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0008976:Clinical Trials [Research Activity]
           Trial
   833   C1096775:clinical trials [Intellectual Product]
   770   C0043227:worked [Occupational Activity]
   770   C0205210:Clinical [Qualitative Concept]

Phrase: "in dementia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0011265:dementia [Mental or Behavioral Dysfunction]
  1000   C0497327:Dementia [Mental or Behavioral Dysfunction]
   900 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "for all"

Phrase: "the major pharmaceutical companies."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0815266:Pharmaceutical Company [Health Care Related Organization]
   827   C0683757:Company [Manufactured Object,Organization]
Processing 00000000.tx.4: See editorial, pp. 

Phrase: "See"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "editorial, pp."
Processing 00000000.tx.5: 9798, this issue. 

Phrase: "9798,"

Phrase: "this issue."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033213:Issue [Finding]
  1000   C1706387:Issue [Intellectual Product]
Processing 00000000.tx.6: ABSTRACT Background Alzheimer's disease management involves symptomatic drug treatments passed by the National Institute for Clinical Excellence. 

Phrase: "ABSTRACT Background Alzheimer's disease management"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0039798:disease management [Functional Concept]
   840   C0376636:Disease Management [Health Care Activity]
           management
   804   C0001554:Management [Occupational Activity]
   804   C1273870:Management [Occupational Activity]
   804   C3273539:Management [Occupation or Discipline]

Phrase: "involves"

Phrase: "symptomatic drug treatments"
Meta Candidates (Total=11; Excluded=8; Pruned=0; Remaining=3)
   827   C0013227:Drug [Pharmacologic Substance]
   827   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827   C1254351:Drug [Pharmacologic Substance]
   793 E C0039798:treatment [Functional Concept]
   793 E C1522326:Treatment [Functional Concept]
   793 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   793 E C1705169:Treatment [Conceptual Entity]
   793 E C3538994:TREATMENT [Research Activity]
   771 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   771 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   734 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "passed by the National Institute"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]
   760   C2828386:Passed [Finding]
   760   C3245503:national [Intellectual Product]

Phrase: "for Clinical Excellence."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   789   C1548784:Excellent [Qualitative Concept]
   789   C1961136:Excellent [Qualitative Concept]
Processing 00000000.tx.7: Disease modification is now the goal. 

Phrase: "Disease modification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0392747:Modification [Functional Concept]
   861   C1554963:modification [Qualitative Concept]

Phrase: "is"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "the goal."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018017:Goal [Intellectual Product]
  1000   C1571704:Goal [Idea or Concept]
Processing 00000000.tx.8: Aims To review current and developmental drugs for Alzheimer's disease, their usage, and the clinical context of known facts and proposed specific models. 

Phrase: "Aims"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1947946:Aim [Idea or Concept]
  1000   C2948600:Aim [Pharmacologic Substance]
  1000   C3540471:AIM [Gene or Genome]
  1000   C3540472:AIM [Functional Concept]
  1000   C3540473:AIMS [Intellectual Product]

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: "current"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0521116:Current [Temporal Concept]
  1000   C1705970:Current [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "developmental drugs for Alzheimer's disease,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0872152:development drugs [Biomedical Occupation or Discipline]
   760   C0013227:Drugs [Pharmacologic Substance]
   726 E C1254351:Drug [Pharmacologic Substance]

Phrase: "their usage,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0457083:Usage [Functional Concept]

Phrase: "and"

Phrase: "the clinical context of known facts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0449255:Context [Finding]
   753   C0542559:Context [Functional Concept]

Phrase: "and"

Phrase: "proposed specific models."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C3161035:Models [Intellectual Product]
Processing 00000000.tx.9: Method A brief evidence-based review was made, using literature where available, or evidence from consensus groups where it was absent. 

Phrase: "Method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025663:Method [Intellectual Product]
  1000   C0449851:Method [Functional Concept]
  1000   C0871511:METHOD [Intellectual Product]

Phrase: "A brief evidence-based review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0282443:Review [Intellectual Product]
   812   C1552617:Review [Idea or Concept]

Phrase: "was"

Phrase: "made"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: ","

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "literature"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0023866:Literature [Intellectual Product]
  1000   C0034036:LITERATURE [Intellectual Product,Manufactured Object]

Phrase: "where available"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0470187:Available [Functional Concept]

Phrase: ","

Phrase: "or"

Phrase: "evidence from consensus groups where"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332120:Evidence [Functional Concept]

Phrase: "it"

Phrase: "was"

Phrase: "absent."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332197:Absent [Quantitative Concept]
  1000   C2699517:ABSENT [Finding]
   928 E C0424530:Absences [Finding]
   928 E C1689985:Absence [Anatomical Abnormality]
Processing 00000000.tx.10: Results There is good evidence to support the use of cholinesterase inhibitors, and perhaps vitamin E. 

Phrase: "Results There"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "is"

Phrase: "good evidence to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332120:Evidence [Functional Concept]

Phrase: "support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "the use of cholinesterase inhibitors,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "and"

Phrase: "perhaps vitamin E."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0042874:Vitamin E [Lipid,Pharmacologic Substance,Vitamin]
   845 E C0591450:Ephynal [Organic Chemical,Pharmacologic Substance,Vitamin]
   827   C0042890:Vitamin [Organic Chemical,Pharmacologic Substance,Vitamin]
Processing 00000000.tx.11: Oestrogen and anti-inflammatory agents show possibility, but there is not enough evidence to support routine use. 

Phrase: "Oestrogen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0014939:Estrogen [Hormone,Pharmacologic Substance,Steroid]
  1000   C2936882:Estrogen [Pharmacologic Substance]
   928 E C0720298:Estrogenic [Hormone,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "anti-inflammatory agents"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0003209:Anti-Inflammatory Agents [Pharmacologic Substance]
           Anti-inflammatory
   913   C0040616:anti-agents [Pharmacologic Substance]
   793   C0450442:Agent [Chemical Viewed Functionally]
   793   C1254351:Agent [Pharmacologic Substance]
   793   C1521826:Agent [Intellectual Product]
   734   C1515999:Anti-inflammatory [Qualitative Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "possibility,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   928   C0332149:Possible [Qualitative Concept]
   928   C1705910:Possible [Qualitative Concept]
   928   C2362652:Possible [Qualitative Concept]

Phrase: "but"

Phrase: "there"

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "enough evidence to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332120:Evidence [Functional Concept]

Phrase: "support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "routine use."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0042153:use [Functional Concept]
   861   C0457083:Use [Functional Concept]
   861   C1947944:Use [Intellectual Product]
Processing 00000000.tx.12: Conclusions Symptomatic treatments exist for Alzheimer's disease. 

Phrase: "Conclusions Symptomatic treatments"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   827   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827   C0231220:Symptomatic [Functional Concept]
   793 E C0039798:treatment [Functional Concept]
   793 E C1522326:Treatment [Functional Concept]
   793 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   793 E C1705169:Treatment [Conceptual Entity]
   793 E C3538994:TREATMENT [Research Activity]

Phrase: "exist for Alzheimer's disease."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   770   C2987476:Exist [Conceptual Entity]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.13: Observational studies and increasing knowledge of brain biology are leading towards further treatment options. 

Phrase: "Observational studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   983   C1518527:Observational Study [Research Activity]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "increasing knowledge of brain biology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0376554:Knowledge [Intellectual Product]

Phrase: "are"

Phrase: "leading towards further treatment options."
Meta Candidates (Total=17; Excluded=6; Pruned=0; Remaining=11)
   806   C0683525:treatment options [Therapeutic or Preventive Procedure]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0332152:Leading [Temporal Concept]
   760   C1517331:Further [Spatial Concept]
   760   C1518601:Options [Functional Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1522538:Leading [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   726 E C0205108:far [Spatial Concept]
   726 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   726 E C1550456:option [Idea or Concept]
   726 E C2348269:Lead [Element, Ion, or Isotope]
   726 E C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.14: Old age psychiatrists have valuable treatments they now have to learn to use. 

Phrase: "Old age psychiatrists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0586880:Old age psychiatrist [Professional or Occupational Group]
   827   C0033872:Psychiatrists [Professional or Occupational Group]
   734   C0231337:Old age [Finding]
   734   C1999167:Old age [Population Group]

Phrase: "have"

Phrase: "valuable treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827 E C0039798:treatment [Functional Concept]
   827 E C1522326:Treatment [Functional Concept]
   827 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   827 E C1705169:Treatment [Conceptual Entity]
   827 E C3538994:TREATMENT [Research Activity]

Phrase: "they now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "have"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "learn"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023185:learn [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "use."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]
Processing 00000000.tx.15: The cholinergic hypothesis of Alzheimer's disease (Davies & Maloney, 1976) has led to the development of a number of strategies to enhance the failing cholinergic neurons and thus the neurotransmitter, acetylcholine. 

Phrase: "The cholinergic hypothesis of Alzheimer's disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1512571:Hypothesis [Idea or Concept]

Phrase: "(Davies & Maloney,"

Phrase: "1976"

Phrase: ")"

Phrase: "has"

Phrase: "led to the development of a number of strategies to"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   739   C0237753:*Number [Quantitative Concept]
   739   C0243107:development [Physiologic Function]
   739   C0449788:Number [Quantitative Concept]
   739   C0678723:Development [Organism Function]
   739   C0679199:strategies [Mental Process]
   739   C1527148:Development [Functional Concept]
   739   C1708698:LED [Manufactured Object]
   706 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   706 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   706 E C1522538:Lead [Functional Concept]
   706 E C2348269:Lead [Element, Ion, or Isotope]
   706 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "the failing cholinergic neurons"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C2333949:Cholinergic Neurons [Cell]
   827   C0027882:Neurons [Cell]
   743 E C0521390:Neuronal [Immunologic Factor]

Phrase: "and"

Phrase: "thus"

Phrase: "the neurotransmitter,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0027908:Neurotransmitter [Neuroreactive Substance or Biogenic Amine]

Phrase: "acetylcholine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001041:Acetylcholine [Neuroreactive Substance or Biogenic Amine,Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.16: The most consistent therapeutic effect has been seen using inhibitors of the enzyme acetylcholinesterase, which cleaves the transmitter in the cholinergic synapse. 

Phrase: "The most consistent therapeutic effect"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1527144:Therapeutic Effect [Health Care Activity]
   812   C1280500:Effect [Qualitative Concept]
   812   C2348382:Effect [Qualitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "seen"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205397:Seen [Qualitative Concept]
   966 E C0042789:see [Organism Function]
   966 E C1947903:See [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "inhibitors of the enzyme acetylcholinesterase,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   797   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   797   C0014432:Enzyme Inhibitors [Pharmacologic Substance]
   797   C1152555:enzyme inhibitors [Molecular Function]
   797   C2756995:Enzyme Inhibitors [Molecular Function]
   781 E C0919438:Enzyme Inhibitor [Pharmacologic Substance]
   781 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   760   C0243077:inhibitors [Chemical Viewed Functionally]
   726 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "which"

Phrase: "cleaves"

Phrase: "the transmitter in the cholinergic synapse."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707723:Transmitter [Manufactured Object]
Processing 00000000.tx.17: Three such compounds have now been licensed for the treatment of Alzheimer's disease: donepezil, rivastigmine and galantamine. 

Phrase: "Three"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205449:Three [Quantitative Concept]

Phrase: "such compounds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205198:Compound [Qualitative Concept]
   966   C1706082:Compound [Chemical]

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "been"

Phrase: "licensed for the treatment of Alzheimer's disease"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   804   C1979617:Alzheimer's disease treatment [Therapeutic or Preventive Procedure]
   778   C0002395:Alzheimer's Disease [Disease or Syndrome]
   778   C1521724:Alzheimer's Disease [Pathologic Function]
   748   C0012634:Disease [Disease or Syndrome]
   748   C0023636:Licensed [Regulation or Law]
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C0242373:licensed [Governmental or Regulatory Activity]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1548573:Licensed [Intellectual Product]
   748   C1705169:Treatment [Conceptual Entity]
   748   C3538994:TREATMENT [Research Activity]
   714 E C1550439:License [Idea or Concept]

Phrase: ":"

Phrase: "donepezil,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: "rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "galantamine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.18: These have increased awareness of Alzheimer's disease, but unfortunately cost pressures have hindered their development in the UK, even though experienced users of donepezil and rivastigmine have found consistent results (Cameron et al, 2000; Evans et al, 2000; Matthews et al, 2000). 

Phrase: "These"

Phrase: "have"

Phrase: "increased awareness of Alzheimer's disease,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0004448:Awareness [Mental Process]

Phrase: "but"

Phrase: "unfortunately"

Phrase: "cost"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0010186:Cost [Quantitative Concept]
  1000   C0220812:cost [Quantitative Concept]

Phrase: "pressures"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0033095:Pressures [Phenomenon or Process]
  1000   C0460139:pressures [Finding]
   966 E C1306345:Pressure [Functional Concept]

Phrase: "have"

Phrase: "hindered"

Phrase: "their development in the UK,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0243107:development [Physiologic Function]
   760   C0678723:Development [Organism Function]
   760   C1527148:Development [Functional Concept]

Phrase: "even"

Phrase: "though"

Phrase: "experienced users of donepezil"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1706077:Users [Human]
   737 E C1548600:User [Idea or Concept]

Phrase: "and"

Phrase: "rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "have"

Phrase: "found consistent results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]

Phrase: "(Cameron et al,"

Phrase: "2000"

Phrase: "; Evans et al,"

Phrase: "2000"

Phrase: "; Matthews et al,"

Phrase: "2000"

Phrase: ")."
Processing 00000000.tx.19: The acetylcholinesterase inhibitors (AChEIs) were considered to be a stepping-stone to better disease-modifying compounds (Bullock, 1998). 

Phrase: "The acetylcholinesterase inhibitors (AChEIs)"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   983 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "a stepping-stone to better disease-modifying compounds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0205198:Compound [Qualitative Concept]
   762   C1706082:Compound [Chemical]

Phrase: "(Bullock,"

Phrase: "1998"

Phrase: ")."
Processing 00000000.tx.20: Although they undoubtedly are, no other class of drug has yet reached the clinic, and AChEIs will remain the main treatment option for some time. 

Phrase: "Although"

Phrase: "they undoubtedly"

Phrase: "are"

Phrase: ","

Phrase: "no"

Phrase: "other class of drug"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0456387:Class [Intellectual Product]
   770   C1705943:Class [Classification]

Phrase: "has"

Phrase: "yet"

Phrase: "reached"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2584321:Reach [Organism Function]

Phrase: "the clinic,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0002424:Clinic [Health Care Related Organization,Manufactured Object]
  1000   C0442592:Clinic [Health Care Related Organization,Manufactured Object]
   928 E C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "AChEIs"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   983 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "will"

Phrase: "remain"

Phrase: "the main treatment option for some time."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0683525:treatment option [Therapeutic or Preventive Procedure]
   748   C1518601:Option [Functional Concept]
   748   C1550456:option [Idea or Concept]
Processing 00000000.tx.21: A variety of protocols for treatment (Harvey, 1999) have been superseded in the UK by the National Institute for Clinical Excellence (2001) guidelines on the use of these three drugs. 

Phrase: "A variety of protocols"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1883525:Variety [Conceptual Entity]
   770   C2346866:Variety [Conceptual Entity]

Phrase: "for treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "(Harvey,"

Phrase: "1999"

Phrase: ")"

Phrase: "have"

Phrase: "been"

Phrase: "superseded in the UK"

Phrase: "by the National Institute"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021622:institute [Organization]
   861   C1272753:Institute [Idea or Concept]

Phrase: "for Clinical Excellence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   789   C1548784:Excellent [Qualitative Concept]
   789   C1961136:Excellent [Qualitative Concept]

Phrase: "(2001"

Phrase: ")"

Phrase: "guidelines on the use of these three drugs."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0162791:Guidelines [Intellectual Product]
   744   C0220845:guidelines [Intellectual Product]
   744   C0282423:guidelines [Intellectual Product]
Processing 00000000.tx.22: PRACTICAL DILEMMAS IN THE USE OF ACETYLCHOLINESTERASE INHIBITORS The AChEI class of drugs all affect the measured domains of dementia in much the same way. 

Phrase: "PRACTICAL DILEMMAS IN THE USE OF ACETYLCHOLINESTERASE INHIBITORS"

Phrase: "The AChEI class of drugs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0456387:Class [Intellectual Product]
   760   C1705943:Class [Classification]

Phrase: "all"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the measured domains of dementia"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1880389:Domain [Functional Concept]
   726   C1883221:Domain [Conceptual Entity]
   726   C3541951:Domain [Intellectual Product]

Phrase: "in much"

Phrase: "the same way."
Processing 00000000.tx.23: The consistency of effect is evident from Fig. 

Phrase: "The consistency of effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332529:Consistency [Qualitative Concept]
   770   C1547017:Consistency [Quantitative Concept]

Phrase: "is"

Phrase: "evident from Fig."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   718   C0332120:Evidence [Functional Concept]
Processing 00000000.tx.24: 1, which shows the cognition scores averaged from the pivotal trials of the three licensed compounds. 

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "which"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the cognition scores"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449820:Scores [Quantitative Concept]

Phrase: "averaged from the pivotal trials of the three licensed compounds."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   739   C0023636:Licensed [Regulation or Law]
   739   C0205449:Three [Quantitative Concept]
   739   C0242373:licensed [Governmental or Regulatory Activity]
   739   C1548573:Licensed [Intellectual Product]
   706   C0008976:Trial [Research Activity]
   706   C0205198:Compound [Qualitative Concept]
   706   C1510992:Average [Quantitative Concept]
   706   C1706082:Compound [Chemical]
   706   C2825518:AVERAGE [Quantitative Concept]
Processing 00000000.tx.25: This is a symptomatic response lasting approximately 8 months, followed by a decline that remains significantly above that of the placebo group for longer periods. 

Phrase: "This"

Phrase: "is"

Phrase: "a symptomatic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "lasting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1517741:Last [Qualitative Concept]

Phrase: "approximately 8 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: "followed by a decline"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   833   C0332283:Followed by [Temporal Concept]
           followed
   737 E C1719822:Follow [Intellectual Product]

Phrase: "that"

Phrase: "remains"

Phrase: "significantly above that of the placebo group"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   748   C0032042:placebo [Therapeutic or Preventive Procedure]
   748   C0441833:Group [Idea or Concept]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1552516:Group [Health Care Related Organization]
   748   C1696465:placebo [Biomedical or Dental Material]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]
   748   C1706408:PLACEBO [Research Activity]

Phrase: "for longer periods."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0439531:/period [Temporal Concept]
   827   C1948053:Period [Temporal Concept]
   777 E C0332182:Periodic [Temporal Concept]
   777 E C1706381:PERIODIC [Intellectual Product]
   755 E C0031084:Periodicities [Temporal Concept]
Processing 00000000.tx.26: This supports the preclinical cholinergic hypotheses (Davies & Maloney, 1976). 

Phrase: "This"

Phrase: "supports"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "the preclinical cholinergic hypotheses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1512571:Hypothesis [Idea or Concept]

Phrase: "(Davies & Maloney,"

Phrase: "1976"

Phrase: ")."
Processing 00000000.tx.27: Exciting as this is, it is only symptomatic treatment at the end of a complex disease process  analogous to the use of levodopa in Parkinson's disease. 

Phrase: "Exciting as this"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C0549255:Excite [Activity]

Phrase: "is"

Phrase: ","

Phrase: "it"

Phrase: "is"

Phrase: "only symptomatic treatment at the end of a complex disease process"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   738   C0039798:treatment [Functional Concept]
   738   C0087111:Treatment [Therapeutic or Preventive Procedure]
   738   C0231220:Symptomatic [Functional Concept]
   738   C1522326:Treatment [Functional Concept]
   738   C1533734:Treatment [Therapeutic or Preventive Procedure]
   738   C1705169:Treatment [Conceptual Entity]
   738   C3538994:TREATMENT [Research Activity]

Phrase: "analogous to the use of levodopa"

Phrase: "in Parkinson's disease."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0030567:Parkinson Disease [Disease or Syndrome]
  1000   C1521736:Parkinson's Disease [Functional Concept]
  1000   C2681933:PARKINSON DISEASE [Gene or Genome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
   761   C1021144:Parkinsonia [Plant]
Processing 00000000.tx.28: The AChEI class continues to present practical and scientific challenges that clinicians need to have resolved; 

Phrase: "The AChEI class"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0456387:Class [Intellectual Product]
   861   C1705943:Class [Classification]

Phrase: "continues"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "present"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: "practical"

Phrase: "and"

Phrase: "scientific"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036397:Scientific [Occupation or Discipline]

Phrase: "challenges"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0798503:Challenge [Clinical Attribute]
  1000   C0805586:Challenge [Health Care Activity]
  1000   C3274764:Challenge [Conceptual Entity]

Phrase: "that clinicians"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0871685:clinicians [Professional or Occupational Group]
   966 E C1550470:clinician [Idea or Concept]

Phrase: "need"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "resolved"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514893:Resolved [Idea or Concept]
  1000   C2699488:Resolved [Conceptual Entity]

Phrase: ";"
Processing 00000000.tx.29: meanwhile, different treatments continue in development. 

Phrase: "meanwhile,"

Phrase: "different treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827 E C0039798:treatment [Functional Concept]
   827 E C1522326:Treatment [Functional Concept]
   827 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   827 E C1705169:Treatment [Conceptual Entity]
   827 E C3538994:TREATMENT [Research Activity]

Phrase: "continue in development."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0243107:development [Physiologic Function]
   790   C0549178:Continue [Idea or Concept]
   790   C0678723:Development [Organism Function]
   790   C1527148:Development [Functional Concept]
   718 E C0458003:Developmental [Qualitative Concept]
Processing 00000000.tx.30: View larger version (18K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(18K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.31: 1 Combined clinical trial data for the three licensed acetylcholinesterase inhibitors: rivastigmine (), donepezil () and galantamine () versus placebo (). 

Phrase: "1 Combined clinical trial data for the three licensed acetylcholinesterase inhibitors"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C1516606:Clinical Data [Intellectual Product]
   738   C1511726:Data [Idea or Concept]
   738   C3245479:data [Medical Device]

Phrase: ":"

Phrase: "rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "("

Phrase: ")"

Phrase: ","

Phrase: "donepezil"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: "("

Phrase: ")"

Phrase: "and"

Phrase: "galantamine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: "("

Phrase: ")"

Phrase: "versus"

Phrase: "placebo"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0032042:placebo [Therapeutic or Preventive Procedure]
  1000   C1696465:placebo [Biomedical or Dental Material]
  1000   C1706408:PLACEBO [Research Activity]

Phrase: "("

Phrase: ")."
Processing 00000000.tx.32: The graph shows the change in cognition scores for patients assessed at 6-week intervals (positive change is improvement). 

Phrase: "The graph"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681493:Graph [Intellectual Product]
  1000   C2698021:Graph [Conceptual Entity]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the change in cognition"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0025320:The change [Physiologic Function]
   770   C0392747:Change [Functional Concept]
   770   C0443172:change [Quantitative Concept]
   770   C1705241:Change [Quantitative Concept]

Phrase: "scores for patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C0449820:Score [Quantitative Concept]

Phrase: "assessed at 6-week intervals"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0332174:/week [Temporal Concept]
   760   C0439230:week [Temporal Concept]
   760   C1272706:intervals [Temporal Concept]
   760   C1516048:Assessed [Activity]
   726 E C1552654:Interval [Idea or Concept]
   726 E C1552713:Interval [Intellectual Product]

Phrase: "(positive change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0392747:Change [Functional Concept]
   861   C0443172:change [Quantitative Concept]
   861   C1705241:Change [Quantitative Concept]

Phrase: "is"

Phrase: "improvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986411:Improvement [Conceptual Entity]

Phrase: ")."
Processing 00000000.tx.33: ADAS-Cog, Alzheimer's Disease Assessment Scale  Cognitive section.  

Phrase: "ADAS-Cog,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3539026:ADAS-COG [Intellectual Product]

Phrase: "Alzheimer's Disease Assessment Scale  Cognitive section."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   858   C1508230:Assessment section [Intellectual Product]
   799   C0205155:Section [Spatial Concept]
   799   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   799   C1522472:Section [Substance]
   799   C1552923:Section [Quantitative Concept]
   799   C1705191:Section [Physical Object]
   734   C0450989:Alzheimer's disease assessment scale [Intellectual Product]
Processing 00000000.tx.34: Who? 

Phrase: "Who?"
Processing 00000000.tx.35: In all trials of AChEIs, a response, as measured by the scales used, was found in an average of 40% of the patients studied (Corey-Bloom et al, 1998; Rogers et al, 1998; Raskind et al, 2000). 

Phrase: "In all trials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0008976:Trial [Research Activity]

Phrase: "of AChEIs,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   983 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "a response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "as"

Phrase: "measured by the scales"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   770   C0175659:Scales [Medical Device]
   770   C0222045:Scales [Body Part, Organ, or Organ Component]
   770   C0444706:Measured [Qualitative Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]
   737 E C0349674:Scale [Intellectual Product]
   737 E C1947916:Scale [Activity]
   737 E C3536777:Scale [Manufactured Object]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: ","

Phrase: "was"

Phrase: "found in an average of 40% of the patients"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   742   C0030705:Patients [Patient or Disabled Group]
   742   C0150312:Found [Quantitative Concept]
   742   C0439509:/40 [Temporal Concept]
   742   C1510992:Average [Quantitative Concept]
   742   C2825518:AVERAGE [Quantitative Concept]
   708 E C0243095:Find [Finding]

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: "(Corey-Bloom et al,"

Phrase: "1998"

Phrase: "; Rogers et al,"

Phrase: "1998"

Phrase: "; Raskind et al,"

Phrase: "2000"

Phrase: ")."
Processing 00000000.tx.36: This compares favourably with most drugs for chronic illness, and all AChEIs have low numbers needed to treat (NNTs) (Livingston & Katona, 2000). 

Phrase: "This"

Phrase: "compares"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "favourably with most drugs"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0013227:Drugs [Pharmacologic Substance]
   737 E C1254351:Drug [Pharmacologic Substance]

Phrase: "for chronic illness,"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0008679:Chronic Illness [Disease or Syndrome]
   861   C0221423:Illness [Finding]
   789 E C0231218:Ill [Sign or Symptom]
   789 E C0332271:worse [Qualitative Concept]
   789 E C1279889:Worse [Finding]
   789 E C1457868:Worse [Qualitative Concept]
   789 E C1522166:Worst [Qualitative Concept]

Phrase: "and"

Phrase: "all AChEIs"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   983 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "have"

Phrase: "low numbers"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0237753:*Number [Quantitative Concept]
   861   C0449788:Number [Quantitative Concept]

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "(NNTs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1417750:NNT [Gene or Genome]

Phrase: ")"

Phrase: "(Livingston & Katona,"

Phrase: "2000"

Phrase: ")."
Processing 00000000.tx.37: Using the scores from published data, donepezil has an NNT of 4, rivastigmine 7 and galantamine 3. 

Phrase: "Using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the scores from published data,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449820:Scores [Quantitative Concept]

Phrase: "donepezil"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: "has"

Phrase: "an NNT of 4,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1417750:NNT [Gene or Genome]

Phrase: "rivastigmine 7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "galantamine 3."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.38: The high placebo response is often questioned, but this is common in mental health studies, where it masks a large non-drug treatment effect. 

Phrase: "The high placebo response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "is"

Phrase: "often"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Often [Temporal Concept]

Phrase: "questioned"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1522634:Question [Intellectual Product]

Phrase: ","

Phrase: "but"

Phrase: "this"

Phrase: "is"

Phrase: "common in mental health studies,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205214:Common [Quantitative Concept]
   760   C1522138:Common [Functional Concept]
   760   C3245511:common [Intellectual Product]

Phrase: "where"

Phrase: "it"

Phrase: "masks"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024861:Mask [Medical Device]
  1000   C1538279:MASK [Gene or Genome]
  1000   C1845191:MASK [Gene or Genome]

Phrase: "a large non-drug treatment effect."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   853   C0728866:Drug effect [Functional Concept]
   853   C0728867:Drug effect [Pathologic Function]
   853   C1411996:drug effect [Biologic Function]
   840   C1518681:Treatment Effect [Finding]
   804   C0039798:treatment [Functional Concept]
   804   C0087111:Treatment [Therapeutic or Preventive Procedure]
   804   C1280500:Effect [Qualitative Concept]
   804   C1522326:Treatment [Functional Concept]
   804   C1533734:Treatment [Therapeutic or Preventive Procedure]
   804   C1705169:Treatment [Conceptual Entity]
   804   C2348382:Effect [Qualitative Concept]
   804   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.39: Responders and non-responders are identified  but our criteria may be too harsh and the nature of a response needs more research and definition. 

Phrase: "Responders"

Phrase: "and"

Phrase: "non-responders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Non [Functional Concept]

Phrase: "are"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "but"

Phrase: "our criteria"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0243161:criteria [Intellectual Product]

Phrase: "may"

Phrase: "be"

Phrase: "too harsh"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0234804:Harshness [Sign or Symptom]

Phrase: "and"

Phrase: "the nature of a response"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0349590:Nature [Idea or Concept]
   760   C1262865:Nature [Functional Concept]

Phrase: "needs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "research"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035168:research [Research Activity]
  1000   C0242481:Research [Research Activity]

Phrase: "and"

Phrase: "definition."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1550452:definition [Idea or Concept]
  1000   C1704788:Definition [Conceptual Entity]
  1000   C3539107:Definition [Intellectual Product]
Processing 00000000.tx.40: Currently no hard predictor of response or non-response has been identified (Schneider & Farlow, 1995). 

Phrase: "Currently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "no hard predictor of response"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2698872:Predictor [Idea or Concept]

Phrase: "or"

Phrase: "non-response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0871261:Response [Organism Attribute]
   861   C1518422:Non [Functional Concept]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "has"

Phrase: "been"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "(Schneider & Farlow,"

Phrase: "1995"

Phrase: ")."
Processing 00000000.tx.41: The APOE4 allele was once suggested as a marker of poor response, but subsequent studies suggested no correlation. 

Phrase: "The APOE4 allele"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3642141:APOE*4 Allele [Gene or Genome]
   861   C0002085:Allele [Gene or Genome]

Phrase: "was"

Phrase: "once"

Phrase: "suggested as a marker of poor response,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   748   C0005516:Marker [Clinical Attribute]
   748   C0032854:Poor [Group Attribute]
   748   C0542537:Poor [Qualitative Concept]
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2700379:Poor [Qualitative Concept]
   748   C2911692:Response [Mental Process]
   714   C1705535:Suggest [Idea or Concept]

Phrase: "but"

Phrase: "subsequent studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "no correlation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707520:Correlation [Qualitative Concept]
Processing 00000000.tx.42: In the absence of valid biological markers for Alzheimer's disease, measuring the effect intervention may have on the disease itself requires all patients to be treated for a reasonable length of time  perhaps up to 6 months. 

Phrase: "In the absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "of valid biological markers"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0005516:Biological Markers [Clinical Attribute]
           Marker
   827   C0005532:Biological [Biomedical Occupation or Discipline]
   827   C0205460:biological [Qualitative Concept]

Phrase: "for Alzheimer's disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "measuring"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:measuring [Qualitative Concept]
  1000   C0449770:measuring [Quantitative Concept]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "the effect intervention"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0886296:intervention [Health Care Activity]
   861   C1273869:Intervention [Health Care Activity]
   861   C1948041:Intervention [Therapeutic or Preventive Procedure]
   789 E C3274035:INTERVENTIONAL [Research Activity]

Phrase: "may"

Phrase: "have on the disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   770   C0012634:Disease [Disease or Syndrome]
   770   C3154893:Have [Idea or Concept]
   770   C3539897:Have [Qualitative Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "itself"

Phrase: "requires"

Phrase: "all patients to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "be"

Phrase: "treated for a reasonable length of time  perhaps"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   744   C0040223:Time [Temporal Concept]
   744   C0332293:treated [Therapeutic or Preventive Procedure]
   744   C1444754:Length [Quantitative Concept]
   744   C1522326:Treated [Functional Concept]
   744   C1706316:LENGTH [Research Activity]
   744   C3541383:Time [Temporal Concept]
   711 E C1292734:TREAT [Functional Concept]

Phrase: "up to 6 months."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]
Processing 00000000.tx.43: In reality, this depends on economics; 

Phrase: "In reality,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0871222:reality [Idea or Concept]
   928 E C0237400:Real [Qualitative Concept]
   928 E C3272377:REAL [Intellectual Product]

Phrase: "this"

Phrase: "depends on economics"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0013556:Economics [Occupation or Discipline]
   790   C0013557:economics [Functional Concept]
   790   C0725813:depend [Medical Device]

Phrase: ";"
Processing 00000000.tx.44: so UK prescribers tend to work in subsets of mild to moderate dementia, excluding institutional patients with more advanced disease, and only prescribing to community-based patients who can have their medication supervised  as now ratified in the NICE guidelines. 

Phrase: "so"

Phrase: "UK prescribers"

Phrase: "tend"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "work in subsets of mild to moderate dementia,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   800   C1299392:Mild to moderate [Qualitative Concept]
           mild moderate
   770   C3494871:Moderate dementia [Mental or Behavioral Dysfunction]
   767   C3494623:Mild dementia [Mental or Behavioral Dysfunction]
   744   C0011265:dementia [Mental or Behavioral Dysfunction]
   744   C0043227:Work [Occupational Activity]
   744   C0205081:Moderate [Qualitative Concept]
   744   C0497327:Dementia [Mental or Behavioral Dysfunction]
   744   C1881878:Moderate [Qualitative Concept]
   744   C2945599:Mild [Qualitative Concept]
   711   C1515021:Subset [Classification]

Phrase: "excluding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0332196:Exclude [Functional Concept]
   966   C2828389:Exclude [Activity]

Phrase: "institutional patients with more advanced disease,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "prescribing to community-based patients"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   764   C1709483:Patient Base [Quantitative Concept]
   760   C0009462:Community [Geographic Area]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0278329:Prescribing [Health Care Activity]
   760   C1527178:Based [Functional Concept]
   760   C1705938:Based [Idea or Concept]
   726 E C0002055:base [Inorganic Chemical]
   726 E C0178499:Base [Chemical Viewed Functionally]
   726 E C1880279:Base [Biomedical or Dental Material]

Phrase: "who"

Phrase: "can"

Phrase: "have"

Phrase: "their medication"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013227:Medication, NOS [Pharmacologic Substance]
  1000   C3244316:medication [Functional Concept]

Phrase: "supervised"

Phrase: "as"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "ratified in the NICE guidelines."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0162791:Guidelines [Intellectual Product]
   760   C0220845:guidelines [Intellectual Product]
   760   C0282423:guidelines [Intellectual Product]
Processing 00000000.tx.45: How? 

Phrase: "How?"
Processing 00000000.tx.46: Various models of prescribing exist, all involving titration of the dose to minimise side-effects  particularly gastrointestinal ones. 

Phrase: "Various models of prescribing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C3161035:Models [Intellectual Product]

Phrase: "exist"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2987476:Exist [Conceptual Entity]

Phrase: ","

Phrase: "all"

Phrase: "involving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involving [Functional Concept]

Phrase: "titration of the dose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0162621:Titration [Laboratory Procedure]
   770   C2983683:TITRATION [Research Activity]

Phrase: "to"

Phrase: "minimise"

Phrase: "side-effects  particularly gastrointestinal ones."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   771   C0205447:One [Quantitative Concept]
Processing 00000000.tx.47: Donepezil has the advantage of having only two dose steps, while rivastigmine and galantamine offer a wider range, making tailoring to individual patients perhaps more precise. 

Phrase: "Donepezil"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: "has"

Phrase: "the advantage of"

Phrase: "having"

Phrase: "only two dose steps,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   812   C1261552:steps [Conceptual Entity]
   779 E C1704379:Step [Functional Concept]
   779 E C1705117:Step [Quantitative Concept]
   779 E C2825408:Step [Manufactured Object]

Phrase: "while"

Phrase: "rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "galantamine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: "offer"

Phrase: "a wider range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1514721:Range [Quantitative Concept]
   861   C2348147:Range [Quantitative Concept]
   861   C3542016:Range [Intellectual Product]

Phrase: "making"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: "tailoring to individual patients perhaps more precise."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0402883:tailoring [Professional or Occupational Group]
Processing 00000000.tx.48: Whichever drug is chosen, the dose should be taken to the maximum tolerated (within the licence), after which at least 3 months of treatment should be given before considering whether there has been inadequate response. 

Phrase: "Whichever drug"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "is"

Phrase: "chosen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707391:Chosen [Activity]

Phrase: ","

Phrase: "the dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "should"

Phrase: "be"

Phrase: "taken to the maximum"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0806909:Maximum [Quantitative Concept]
   770   C1552615:maximum [Quantitative Concept]
   770   C1883727:Taken [Conceptual Entity]
   770   C2826546:MAXIMUM [Quantitative Concept]
   737 E C1515187:Take [Health Care Activity]

Phrase: "tolerated"

Phrase: "("

Phrase: "within the licence"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0023636:License [Regulation or Law]
  1000   C1550439:License [Idea or Concept]
   928 E C0242373:licensed [Governmental or Regulatory Activity]
   928 E C1548573:Licensed [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "after"

Phrase: "which at least 3 months of treatment"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C0439231:months [Temporal Concept]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1705169:Treatment [Conceptual Entity]
   748   C3538994:TREATMENT [Research Activity]
   714 E C0439507:/month [Temporal Concept]

Phrase: "should"

Phrase: "be"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "before"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332152:Before [Temporal Concept]
  1000   C1705850:Before [Intellectual Product]

Phrase: "considering"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considering [Idea or Concept]

Phrase: "whether"

Phrase: "there"

Phrase: "has"

Phrase: "been"

Phrase: "inadequate response."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
Processing 00000000.tx.49: Rigidity may mean that late responders miss out on potential benefit  but within a limited budget, it will allow more patients exposure to treatment. 

Phrase: "Rigidity"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0026837:Rigidity, NOS [Sign or Symptom]
  1000   C0700109:rigidity [Natural Phenomenon or Process]
   928 E C0231517:Rigid [Individual Behavior]
   928 E C1882952:RIGID [Phenomenon or Process]

Phrase: "may"

Phrase: "mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "that late responders"

Phrase: "miss"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349206:Miss [Conceptual Entity]

Phrase: "out on potential benefit"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0439787:Out [Spatial Concept]
   770   C0814225:Benefit [Quantitative Concept]
   770   C0849355:Out [Qualitative Concept]
   770   C3245505:Potential [Qualitative Concept]

Phrase: "but within a limited budget,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0006347:Budget [Intellectual Product]
   760   C0233535:but [Mental or Behavioral Dysfunction]
   760   C0439801:Limited [Functional Concept]
   760   C3542948:Limited [Intellectual Product]

Phrase: "it"

Phrase: "will"

Phrase: "allow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allow [Social Behavior]

Phrase: "more patients exposure to treatment."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0332157:Exposure to [Clinical Attribute]
           Exposure
   760   C0274281:Exposure, NOS [Injury or Poisoning]
Processing 00000000.tx.50: If one drug does not work or has intolerable side-effects, then another should be tried; 

Phrase: "If"

Phrase: "one drug"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "or"

Phrase: "has"

Phrase: "intolerable side-effects,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   901   C0001688:side effects [Functional Concept]
   867 E C0879626:Side Effect [Pathologic Function]
   827   C0441987:Side [Spatial Concept]
   827   C1280500:effects [Qualitative Concept]
   793 E C2348382:Effect [Qualitative Concept]

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "another"

Phrase: "should"

Phrase: "be"

Phrase: "tried"

Phrase: ";"
Processing 00000000.tx.51: although the three drugs belong to the same class, they are all different. 

Phrase: "although"

Phrase: "the three drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "belong to the same class,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0445247:Same [Qualitative Concept]
   760   C0456387:Class [Intellectual Product]
   760   C1705943:Class [Classification]

Phrase: "they"

Phrase: "are"

Phrase: "all different."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1705242:Different [Qualitative Concept]
   928 E C1705241:*Difference [Quantitative Concept]
   900 E C0443199:Differential [Qualitative Concept]
Processing 00000000.tx.52: There is no published information on switching the drugs. 

Phrase: "There"

Phrase: "is"

Phrase: "no published information on"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C1546437:No Information [Qualitative Concept]
   819   C1549058:No Information [Idea or Concept]
   770   C1533716:Information [Idea or Concept]

Phrase: "switching"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707719:Switch [Manufactured Object]

Phrase: "the drugs."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.53: Convention when switching drugs is to leave an interval of five times the half-life of the first drug before commencing the second (that is, 60 hours for rivastigmine and 15 days for donepezil). 

Phrase: "Convention"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0086047:convention [Human-caused Phenomenon or Process]
  1000   C0439858:Convention [Qualitative Concept]

Phrase: "when"

Phrase: "switching"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707719:Switch [Manufactured Object]

Phrase: "drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "is"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "leave"

Phrase: "an interval of five times"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   781   C0872291:Time Interval [Temporal Concept]
   760   C1272706:Interval [Temporal Concept]
   760   C1552654:Interval [Idea or Concept]
   760   C1552713:Interval [Intellectual Product]

Phrase: "the half-life of the first drug"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0678761:drug half-life [Quantitative Concept]
   778   C0018517:Half-Life [Temporal Concept]
   748   C0376558:Life [Idea or Concept]
   748   C2825407:Half [Quantitative Concept]

Phrase: "before commencing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C3274784:Commence [Activity]

Phrase: "the second"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0205436:Second [Quantitative Concept]
  1000   C0457385:Second [Temporal Concept]
  1000   C0565930:/second [Quantitative Concept]
  1000   C1561503:second [Idea or Concept]
  1000   C1705190:Second [Qualitative Concept]
   928 E C0027627:secondary [Neoplastic Process]
   928 E C0175668:Secondary [Temporal Concept]

Phrase: "("

Phrase: "that"

Phrase: "is"

Phrase: ","

Phrase: "60 hours for rivastigmine"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0439227:hours [Temporal Concept]
   737 E C0564385:/hour [Quantitative Concept]

Phrase: "and"

Phrase: "15 days for donepezil"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   770   C0439228:days [Temporal Concept]
   737 E C0332173:/day [Temporal Concept]
   737 E C0439505:/day [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.54: Consensus suggests that 3 days should be left after treatment with rivastigmine or galantamine, while a week should be left following donepezil treatment. 

Phrase: "Consensus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0376298:Consensus [Social Behavior]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that 3 days"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1442459:3 Days [Temporal Concept]
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "should"

Phrase: "be"

Phrase: "left after treatment"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   882   C0001758:After-Treatment [Health Care Activity]
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C0205091:Left [Spatial Concept]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1552822:left [Functional Concept]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "with rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "galantamine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: "while"

Phrase: "a week"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332174:/week [Temporal Concept]
  1000   C0439230:week [Temporal Concept]

Phrase: "should"

Phrase: "be"

Phrase: "left"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205091:Left [Spatial Concept]
  1000   C1552822:left [Functional Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "donepezil treatment."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.55: This is based on clinical practice  no controlled trial has been published. 

Phrase: "This"

Phrase: "is"

Phrase: "based on clinical"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0205210:Clinical [Qualitative Concept]
   790   C1527178:Based [Functional Concept]
   790   C1705938:Based [Idea or Concept]
   756 E C0002055:base [Inorganic Chemical]
   756 E C0178499:Base [Chemical Viewed Functionally]
   756 E C1880279:Base [Biomedical or Dental Material]

Phrase: "practice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237607:practice [Mental Process]
  1000   C3245512:practice [Intellectual Product]

Phrase: "no controlled trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008976:Trial [Research Activity]

Phrase: "has"

Phrase: "been"

Phrase: "published."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034037:Published [Occupational Activity]
  1000   C1704324:Published [Intellectual Product]
Processing 00000000.tx.56: Which? 

Phrase: "Which?"
Processing 00000000.tx.57: The three drugs are similar yet have different individual characteristics (Table 1). 

Phrase: "The three drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are"

Phrase: "similar yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2348205:Similar [Qualitative Concept]

Phrase: "have"

Phrase: "different individual characteristics"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1521970:Characteristics [Qualitative Concept]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.58: How clinically relevant the differences are is unproven but interesting hypotheses are arising out of them. 

Phrase: "How clinically relevant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347946:Relevant [Qualitative Concept]

Phrase: "the differences"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1705241:*Difference [Quantitative Concept]
   966   C1705242:Difference [Qualitative Concept]
   916 E C0443199:Differential [Qualitative Concept]

Phrase: "are"

Phrase: "is"

Phrase: "unproven"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456370:Unproven [Qualitative Concept]

Phrase: "but"

Phrase: "interesting hypotheses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1512571:Hypothesis [Idea or Concept]

Phrase: "are"

Phrase: "arising out of them."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0332284:arising [Qualitative Concept]
   770   C0439787:Out [Spatial Concept]
   770   C0849355:Out [Qualitative Concept]
Processing 00000000.tx.59: View this table: [in this window] [in a new window]  Table 1 Attributes of the three licensed acetylcholinesterase inhibitors  Donepezil Donepezil is very selective for acetylcholinesterase (AChE). 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1 Attributes of the three licensed acetylcholinesterase inhibitors  Donepezil Donepezil"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   704   C0449234:Attribute [Idea or Concept]
   704   C1704772:Attribute [Conceptual Entity]
   704   C1882133:Attribute [Qualitative Concept]

Phrase: "is"

Phrase: "very selective for acetylcholinesterase (AChE)."
Processing 00000000.tx.60: This selectivity is claimed to reduce its side-effect profile, but published clinical data have not shown increased tolerability. 

Phrase: "This selectivity"

Phrase: "is"

Phrase: "claimed"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reduce"

Phrase: "its side-effect profile,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0879626:Side Effect [Pathologic Function]
   827   C0441987:Side [Spatial Concept]
   827   C1280500:Effect [Qualitative Concept]
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]
   827   C2348382:Effect [Qualitative Concept]

Phrase: "but"

Phrase: "published clinical data"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1516606:Clinical Data [Intellectual Product]
   827   C1511726:Data [Idea or Concept]
   827   C3245479:data [Medical Device]

Phrase: "have"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "tolerability."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3274448:TOLERABILITY [Research Activity]
Processing 00000000.tx.61: Paradoxically, in Alzheimer's disease the level of AChE falls as the disease progresses (Arendt, 1992), matched by a rise in butyrylcholinesterase (BuChE)  the function of which is unknown, but it forms part of the plaques and appears to come from the activated glial cells. 

Phrase: "Paradoxically,"

Phrase: "in Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "the level of AChE"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0441889:Level [Qualitative Concept]
   770   C0456079:Level [Classification]
   770   C1547707:Level [Geographic Area]
   770   C2946261:Level [Pharmacologic Substance]

Phrase: "falls as the disease progresses"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0012634:Disease [Disease or Syndrome]
   760   C0085639:Fall [Finding]
   760   C0238715:Fall [Temporal Concept]
   760   C1272688:progress [Functional Concept]
   760   C1280477:Progress [Functional Concept]
   704 E C1836721:MALS [Finding]
   704 E C3538764:MALS [Gene or Genome]
   704 E C3540595:MAL [Gene or Genome]

Phrase: "(Arendt,"

Phrase: "1992"

Phrase: ")"

Phrase: ","

Phrase: "matched by a rise"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0150103:matched [Research Activity]
   770   C1708943:Matched [Qualitative Concept]

Phrase: "in butyrylcholinesterase (BuChE)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0728810:Butyrylcholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412756:BUTYRYLCHOLINESTERASE [Gene or Genome]

Phrase: "the function of which"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0031843:function [Physiologic Function]
   770   C0542341:Function [Functional Concept]
   770   C0700205:FUNCTION [Classification]
   770   C1705273:Function [Intellectual Product]

Phrase: "is"

Phrase: "unknown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439673:Unknown [Qualitative Concept]

Phrase: "but"

Phrase: "it"

Phrase: "forms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "part of the plaques"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1292711:Part of [Spatial Concept]
   770   C0449719:Part [Spatial Concept]
   770   C1709471:Part [Quantitative Concept]

Phrase: "and"

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "come from the activated glial cells."
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   790   C0027836:Glial Cells [Cell]
           Glial
   753   C0007634:Cells [Cell]
   753   C1879547:Activated [Activity]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1515877:Activate [Functional Concept]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.62: What BuChE inhibition means is unclear, but rivastigmine and galantamine inhibit it, donepezil does not  they may work differently in later disease, although no published evidence has supported this. 

Phrase: "What BuChE inhibition means"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C1704970:Means [Conceptual Entity]
   793 E C0444504:Mean [Quantitative Concept]
   793 E C2347634:Mean [Quantitative Concept]
   793 E C2348143:Mean [Quantitative Concept]

Phrase: "is"

Phrase: "unclear,"

Phrase: "but"

Phrase: "rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "galantamine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "it,"

Phrase: "donepezil"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "they"

Phrase: "may"

Phrase: "work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "differently in later disease,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0012634:Disease [Disease or Syndrome]
   737   C0205087:Late [Temporal Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "although"

Phrase: "no published evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332120:Evidence [Functional Concept]

Phrase: "has"

Phrase: "supported"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521721:Supported [Conceptual Entity]
   966 E C0183683:Support [Medical Device]

Phrase: "this."
Processing 00000000.tx.63: Rivastigmine Rivastigmine preferentially inhibits one of the four AChE subtypes  G1, found particularly in the hypothalamus and cortex. 

Phrase: "Rivastigmine Rivastigmine preferentially"

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "one of the four AChE subtypes  G1,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205447:One [Quantitative Concept]

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "particularly in the hypothalamus"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0020663:Hypothalamus [Body Part, Organ, or Organ Component]
   770   C1280712:Hypothalamus [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "cortex."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0007776:Cortex [Body Part, Organ, or Organ Component]
  1000   C1176472:Cortex [Body Part, Organ, or Organ Component]
  1000   C2700441:Cortex [Plant]
Processing 00000000.tx.64: This subtype is implicated in plaque maturation, but whether there is any added clinical benefit to this specificity is again unproven. 

Phrase: "This subtype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449560:Subtype [Classification]

Phrase: "is"

Phrase: "implicated in plaque maturation,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0011389:Plaque [Disease or Syndrome]
   770   C0332461:Plaque [Finding]
   770   C0333463:plaque [Acquired Abnormality]
   770   C0678723:Maturation [Organism Function]
   770   C0870861:maturation [Phenomenon or Process]
   770   C1254042:Maturation [Physiologic Function]

Phrase: "but"

Phrase: "whether"

Phrase: "there"

Phrase: "is"

Phrase: "any added clinical benefit to this specificity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0814225:Benefit [Quantitative Concept]

Phrase: "is"

Phrase: "again unproven."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0456370:Unproven [Qualitative Concept]
Processing 00000000.tx.65: Galantamine Galantamine produces an effect on presynaptic nicotinic receptors called allosteric modulation (as does physostigmine and codeine). 

Phrase: "Galantamine Galantamine"

Phrase: "produces"

Phrase: "an effect on presynaptic nicotinic receptors"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0549428:Nicotinic Effect [Finding]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "called"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0679006:Call [Mental Process]
   966   C1947967:Call [Functional Concept]

Phrase: "allosteric modulation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0443264:Modulation [Spatial Concept]

Phrase: "("

Phrase: "as"

Phrase: "does"

Phrase: "physostigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031849:Physostigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "codeine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0009214:Codeine [Organic Chemical,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.66: This produces increased amounts of acetylcholine in the synapse by a direct effect on presynaptic release, but again, the clinical impact is unknown and published evidence as to its significance and desirability is required. 

Phrase: "This"

Phrase: "produces"

Phrase: "increased amounts of acetylcholine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1265611:amounts [Quantitative Concept]

Phrase: "in the synapse"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039062:Synapse [Body Space or Junction]

Phrase: "by a direct effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "on presynaptic release,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "but"

Phrase: "again,"

Phrase: "the clinical impact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1825598:IMPACT [Gene or Genome]

Phrase: "is"

Phrase: "unknown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439673:Unknown [Qualitative Concept]

Phrase: "and"

Phrase: "published evidence as to its significance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0332120:Evidence [Functional Concept]

Phrase: "and"

Phrase: "desirability"

Phrase: "is"

Phrase: "required."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]
Processing 00000000.tx.67: It may be that modulation, rather than agonism, protects against downregulation of post-synaptic receptors. 

Phrase: "It"

Phrase: "may"

Phrase: "be"

Phrase: "that modulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:Modulation [Spatial Concept]

Phrase: "rather than"

Phrase: "agonism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   900   C0243192:agonists [Pharmacologic Substance]
   900   C2987634:Agonist [Pharmacologic Substance]

Phrase: "protects against downregulation of post-synaptic receptors."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0039064:Synaptic Receptors [Amino Acid, Peptide, or Protein,Receptor]
   757   C0949469:Receptor Down-Regulation [Molecular Function]
   748   C0013081:Down-Regulation [Cell Function,Molecular Function]
   748   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   748   C0687676:Post [Temporal Concept]
   748   C1704687:Post [Manufactured Object]
Processing 00000000.tx.68: This may allow the drug to work longer, but further studies are needed to confirm this. 

Phrase: "This"

Phrase: "may"

Phrase: "allow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allow [Social Behavior]

Phrase: "the drug to"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "longer,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205166:Long [Qualitative Concept]
   966   C1706317:Long [Qualitative Concept]

Phrase: "but"

Phrase: "further studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "are"

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "confirm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521093:confirm [Qualitative Concept]
  1000   C0750484:confirm [Idea or Concept]
  1000   C1456348:Confirm [Qualitative Concept]

Phrase: "this."
Processing 00000000.tx.69: Modulation also improves attention, and this has been demonstrated with galantamine but not with donepezil or rivastigmine in Alzheimer's disease. 

Phrase: "Modulation also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0443264:Modulation [Spatial Concept]

Phrase: "improves"

Phrase: "attention,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004268:Attention [Mental Process]

Phrase: "and"

Phrase: "this"

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated with galantamine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: "but"

Phrase: "not with donepezil"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]
   790   C1518422:Not [Functional Concept]

Phrase: "or"

Phrase: "rivastigmine in Alzheimer's disease."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.70: When? 

Phrase: "When?"
Processing 00000000.tx.71: The drugs are licensed for mild to moderate Alzheimer's disease. 

Phrase: "The drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are"

Phrase: "licensed for mild to moderate Alzheimer's disease."
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   814   C1299392:Mild to moderate [Qualitative Concept]
           mild moderate
   778   C0002395:Alzheimer's Disease [Disease or Syndrome]
   778   C1521724:Alzheimer's Disease [Pathologic Function]
   748   C0012634:Disease [Disease or Syndrome]
   748   C0023636:Licensed [Regulation or Law]
   748   C0205081:Moderate [Qualitative Concept]
   748   C0242373:licensed [Governmental or Regulatory Activity]
   748   C1548573:Licensed [Intellectual Product]
   748   C1881878:Moderate [Qualitative Concept]
   748   C2945599:Mild [Qualitative Concept]
   714 E C1550439:License [Idea or Concept]
Processing 00000000.tx.72: Patients with mild disease already have significant illness and should receive treatment, even with minimal symptoms. 

Phrase: "Patients with mild disease already"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "significant illness"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0221423:Illness [Finding]
   789 E C0231218:Ill [Sign or Symptom]
   789 E C0332271:worse [Qualitative Concept]
   789 E C1279889:Worse [Finding]
   789 E C1457868:Worse [Qualitative Concept]
   789 E C1522166:Worst [Qualitative Concept]

Phrase: "and"

Phrase: "should"

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "treatment,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "even with minimal symptoms."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0547040:Minimal [Qualitative Concept]
   770   C0683368:symptoms [Functional Concept]
   770   C1457887:Symptoms [Sign or Symptom]
   770   C1524031:MINIMAL [Qualitative Concept]
   770   C2945599:Minimal [Qualitative Concept]
Processing 00000000.tx.73: Treating mildly affected patients will mean smaller responses, and protocols should reflect this  long-term follow-up being needed to show any continuing effect beyond that expected from clinical trials. 

Phrase: "Treating"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treating [Therapeutic or Preventive Procedure]
  1000   C1522326:Treating [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "mildly affected patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0522476:affected patients [Qualitative Concept]
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "will"

Phrase: "mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "smaller responses,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0871261:responses [Organism Attribute]
   827 E C1704632:Response [Finding]
   827 E C1706817:Response [Intellectual Product]
   827 E C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "protocols"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0442711:Protocols [Intellectual Product]
   966 E C1507394:Protocol [Intellectual Product]
   966 E C1522729:Protocol [Intellectual Product]
   966 E C2348563:Protocol [Intellectual Product]

Phrase: "should"

Phrase: "reflect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0558058:reflect [Mental Process]

Phrase: "this  long-term follow-up"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C1517942:Long-term Follow-up [Health Care Activity]
   861   C0589120:Follow-up [Finding]
   861   C1522577:follow-up [Health Care Activity]
   861   C1704685:FOLLOW-UP [Intellectual Product]
   861   C3274571:FOLLOW-UP [Health Care Activity]
   812   C0332283:follow [Temporal Concept]
   812   C1719822:Follow [Intellectual Product]

Phrase: "being"

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "any continuing effect beyond that"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "expected from clinical trials."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0008976:Clinical Trials [Research Activity]
           Trial
   833   C1096775:clinical trials [Intellectual Product]
   770   C0205210:Clinical [Qualitative Concept]
   770   C1517001:Expected [Idea or Concept]
Processing 00000000.tx.74: Moderate disease covers a wide range of morbidity: in trials down to a Mini-Mental State Examination (MMSE; Folstein et al, 1975) score of 10, but in NICE guidelines down to 12. 

Phrase: "Moderate disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "covers"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0180153:cover [Medical Device]
  1000   C1707529:Cover [Medical Device]
  1000   C1999244:Cover [Functional Concept]

Phrase: "a wide range of morbidity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1514721:Range [Quantitative Concept]
   760   C2348147:Range [Quantitative Concept]
   760   C3542016:Range [Intellectual Product]

Phrase: ":"

Phrase: "in trials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0008976:Trial [Research Activity]

Phrase: "down"

Phrase: "to a Mini-Mental State Examination"
Meta Candidates (Total=15; Excluded=7; Pruned=0; Remaining=8)
  1000   C0451306:Mini-mental state examination [Diagnostic Procedure]
   923   C0850338:mental state examination [Therapeutic or Preventive Procedure]
   861   C0278060:Mental state [Finding]
   812   C0229992:mental [Mental Process]
   812   C0445542:Mini [Organism Attribute]
   812   C1301808:State [Geographic Area]
   812   C1442792:State [Functional Concept]
   812   C3148680:State [Geographic Area]
   729 E C0229993:Psychic [Functional Concept]
   712 E C0011980:Diaphragm [Body Part, Organ, or Organ Component]
   712 E C0042241:DIAPHRAGM [Medical Device]
   712 E C1279038:Diaphragm [Body Part, Organ, or Organ Component]
   712 E C1705367:Diaphragm [Medical Device]
   701 E C0086045:mindfulness [Mental Process]
   701 E C3542996:Mindfulness [Mental Process]

Phrase: "(MMSE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0451306:MMSE [Diagnostic Procedure]
  1000   C3538742:MMSE [Intellectual Product]

Phrase: "; Folstein et al,"

Phrase: "1975"

Phrase: ")"

Phrase: "score of 10,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0449820:Score [Quantitative Concept]

Phrase: "but in NICE guidelines"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0162791:Guidelines [Intellectual Product]
   770   C0220845:guidelines [Intellectual Product]
   770   C0233535:but [Mental or Behavioral Dysfunction]
   770   C0282423:guidelines [Intellectual Product]

Phrase: "down"

Phrase: "to 12."
Processing 00000000.tx.75: Patients scoring at the lower end of the range have a host of symptoms, and AChEIs here may be as valuable for their symptomatic effects on behaviour as for their effect on the underlying disease. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "scoring at the lower end of the range"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   744   C0441994:Lower [Spatial Concept]
   744   C0444930:End [Spatial Concept]
   744   C0449820:scoring [Quantitative Concept]
   744   C1514721:Range [Quantitative Concept]
   744   C1548802:Lower [Body Location or Region]
   744   C1552081:scoring [Idea or Concept]
   744   C2003888:Lower [Activity]
   744   C2348147:Range [Quantitative Concept]
   744   C2746065:End [Temporal Concept]
   744   C3542016:Range [Intellectual Product]

Phrase: "have"

Phrase: "a host of symptoms,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1167395:Host [Organism]

Phrase: "and"

Phrase: "AChEIs here"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   901   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   884 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   827   C0243077:inhibitors [Chemical Viewed Functionally]
   793 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "may"

Phrase: "be"

Phrase: "as"

Phrase: "valuable for their symptomatic effects"

Phrase: "on behaviour"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0004927:Behavior [Individual Behavior]
  1000   C2707008:Behavior [Clinical Attribute]
   928 E C2986890:Behavioral [Idea or Concept]

Phrase: "as for their effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "on the underlying disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.76: Trial data with metrifonate (another AChEI, which was withdrawn because of side-effects) showed improvement in neuropsychiatric symptoms in Alzheimer's disease  especially in apathy, hallucinations and agitation (Cummings et al, 1998). 

Phrase: "Trial data with metrifonate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1511726:Data [Idea or Concept]
   770   C3245479:data [Medical Device]

Phrase: "("

Phrase: "another AChEI,"

Phrase: "which"

Phrase: "was"

Phrase: "withdrawn because of side-effects"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C0001688:side effects [Functional Concept]
   773 E C0879626:Side Effect [Pathologic Function]
   760   C0424092:Withdrawn [Finding]
   760   C0441987:Side [Spatial Concept]
   760   C1280500:effects [Qualitative Concept]
   760   C2349954:Withdrawn [Activity]
   760   C2825032:Withdrawn [Mental or Behavioral Dysfunction]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: ")"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "improvement in neuropsychiatric symptoms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2986411:Improvement [Conceptual Entity]

Phrase: "in Alzheimer's disease  especially"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0002395:Alzheimer's Disease [Disease or Syndrome]
   901   C1521724:Alzheimer's Disease [Pathologic Function]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "in apathy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0085632:Apathy [Sign or Symptom]

Phrase: "hallucinations"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0018524:Hallucinations [Mental or Behavioral Dysfunction]

Phrase: "and"

Phrase: "agitation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0085631:Agitation [Sign or Symptom]

Phrase: "(Cummings et al,"

Phrase: "1998"

Phrase: ")."
Processing 00000000.tx.77: This effect is more noticeable in dementia with Lewy bodies where improvements in both MMSE scores and neuropsychiatric symptoms have been demonstrated with rivastigmine (McKeith et al, 2000). 

Phrase: "This effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "more noticeable in dementia"

Phrase: "with Lewy bodies where improvements"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C2986411:Improvement [Conceptual Entity]

Phrase: "in both MMSE scores"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449820:Scores [Quantitative Concept]

Phrase: "and"

Phrase: "neuropsychiatric symptoms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0683368:symptoms [Functional Concept]
   861   C1457887:Symptoms [Sign or Symptom]

Phrase: "have"

Phrase: "been"

Phrase: "demonstrated with rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "(McKeith et al,"

Phrase: "2000"

Phrase: ")."
Processing 00000000.tx.78: This suggests that dementia should be treated at any time, with symptomatic delay and retention of qualify of life being the aim early in the disease, moving towards symptomatic relief as progression occurs. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that dementia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0011265:dementia [Mental or Behavioral Dysfunction]
  1000   C0497327:Dementia [Mental or Behavioral Dysfunction]
   900 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "should"

Phrase: "be"

Phrase: "treated at any time,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0040223:Time [Temporal Concept]
   770   C0332293:treated [Therapeutic or Preventive Procedure]
   770   C1522326:Treated [Functional Concept]
   770   C3541383:Time [Temporal Concept]
   737 E C1292734:TREAT [Functional Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "with symptomatic delay"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205421:Delay [Temporal Concept]

Phrase: "and"

Phrase: "retention of"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0035280:Retention [Mental Process]
   833   C0333117:Retention [Functional Concept]
   833   C1753315:retention [Cell Function]

Phrase: "qualify of life"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0376558:Life [Idea or Concept]
   706 E C0595998:lives [Finding]

Phrase: "being"

Phrase: "the aim early in the disease,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C1947946:Aim [Idea or Concept]
   753   C2948600:Aim [Pharmacologic Substance]
   753   C3540471:AIM [Gene or Genome]
   753   C3540472:AIM [Functional Concept]

Phrase: "moving towards symptomatic relief"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   833   C3242309:symptomatic relief [Idea or Concept]
   770   C0231220:Symptomatic [Functional Concept]
   770   C0560560:Moving [Organism Function]
   770   C0564405:Relief [Finding]
   737 E C0578671:move [Finding]
   737 E C1269909:move [Functional Concept]
   737 E C1299988:move [Functional Concept]
   737 E C2699029:Move [Activity]

Phrase: "as progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242656:progression [Pathologic Function]
  1000   C0449258:Progression [Functional Concept]

Phrase: "occurs."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1709305:Occur [Activity]
  1000   C2745955:OCCUR [Temporal Concept]
Processing 00000000.tx.79: No published results are available for severe dementia, though open-label follow-up from trials suggests that these drugs continue working as the cholinergic deficit increases. 

Phrase: "No published results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "are"

Phrase: "available for severe dementia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0470187:Available [Functional Concept]

Phrase: "though"

Phrase: "open-label follow-up from trials"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0589120:Follow-up [Finding]
   790   C1522577:follow-up [Health Care Activity]
   790   C1704685:FOLLOW-UP [Intellectual Product]
   790   C3274571:FOLLOW-UP [Health Care Activity]
   753   C0332283:follow [Temporal Concept]
   753   C1719822:Follow [Intellectual Product]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "these drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "continue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "working as the cholinergic deficit increases."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0043227:Working [Occupational Activity]
Processing 00000000.tx.80: What? 

Phrase: "What?"
Processing 00000000.tx.81: What about AChEIs in other dementias, plus other cholinergic therapies? 

Phrase: "What about AChEIs in other dementias,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   778   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   762 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   748   C0243077:inhibitors [Chemical Viewed Functionally]
   714 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "plus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332287:Plus [Qualitative Concept]

Phrase: "other cholinergic therapies?"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0087111:therapies [Therapeutic or Preventive Procedure]
   827 E C0039798:therapy [Functional Concept]
   827 E C1363945:Therapy [Finding]
Processing 00000000.tx.82: Clinical trials are ongoing with AChEIs in vascular dementia and mixed dementia. 

Phrase: "Clinical trials"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0008976:Clinical Trials [Research Activity]
           Trial
  1000   C1096775:clinical trials [Intellectual Product]
   861   C0205210:Clinical [Qualitative Concept]

Phrase: "are"

Phrase: "ongoing with AChEIs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0549178:ONGOING [Idea or Concept]

Phrase: "in vascular dementia"
Meta Candidates (Total=14; Excluded=8; Pruned=0; Remaining=6)
  1000   C0011269:Dementia, Vascular [Disease or Syndrome]
   861   C0005847:vascular [Body Part, Organ, or Organ Component]
   861   C0011265:dementia [Mental or Behavioral Dysfunction]
   861   C0497327:Dementia [Mental or Behavioral Dysfunction]
   861   C1558950:VASCULAR [Finding]
   861   C1801960:Vascular [Qualitative Concept]
   805 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   805 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C0005767:Blood [Tissue]
   761 E C0005768:blood [Body Substance]
   761 E C0229664:Blood [Body Substance]
   761 E C0392895:Bloods [Population Group]
   761 E C0860630:dement [Mental or Behavioral Dysfunction]
   745 E C0333275:Bloody [Qualitative Concept]

Phrase: "and"

Phrase: "mixed dementia."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C3532942:Mixed dementia [Mental or Behavioral Dysfunction]
   861   C0011265:dementia [Mental or Behavioral Dysfunction]
   861   C0497327:Dementia [Mental or Behavioral Dysfunction]
   761 E C0860630:dement [Mental or Behavioral Dysfunction]
Processing 00000000.tx.83: No result is available as yet, but as the cholinergic system is implicated in these disorders it is hoped that findings will be positive. 

Phrase: "No result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "is"

Phrase: "available as yet,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0470187:Available [Functional Concept]

Phrase: "but as the cholinergic system"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0684164:cholinergic system [Biologically Active Substance]
   760   C0233535:but [Mental or Behavioral Dysfunction]
   760   C0449913:System [Functional Concept]
   760   C0599668:cholinergic [Functional Concept]
   760   C1553451:System [Manufactured Object]
   760   C1704459:System [Medical Device]

Phrase: "is"

Phrase: "implicated in these disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0012634:Disorders [Disease or Syndrome]

Phrase: "it"

Phrase: "is"

Phrase: "hoped"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0392347:Hope [Mental Process]

Phrase: "that findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "will"

Phrase: "be"

Phrase: "positive."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0439178:% Positive [Quantitative Concept]
  1000   C1446409:Positive [Qualitative Concept]
  1000   C1514241:Positive [Finding]
  1000   C2825490:Positive [Qualitative Concept]
Processing 00000000.tx.84: A study of rivastigmine in dementia with Lewy bodies has produced positive results (McKeith et al, 2000). 

Phrase: "A study of rivastigmine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "in dementia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0011265:dementia [Mental or Behavioral Dysfunction]
  1000   C0497327:Dementia [Mental or Behavioral Dysfunction]
   900 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "with Lewy bodies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0085200:Lewy Bodies [Cell Component]
   861   C0242821:bodies [Human]
   861   C1995017:Bodies [Cell Component]
   827 E C0460148:Body [Anatomical Structure]
   827 E C1268086:Body [Anatomical Structure]

Phrase: "has"

Phrase: "produced positive results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]

Phrase: "(McKeith et al,"

Phrase: "2000"

Phrase: ")."
Processing 00000000.tx.85: Acetylcholinesterases are being studied as a potential treatment in mild cognitive impairment  a rational assumption as 55% of patients with this problem go on to develop Alzheimer's disease, and intervention here may have a profound effect on the burden of disease overall. 

Phrase: "Acetylcholinesterases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001044:acetylcholinesterases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "are"

Phrase: "being"

Phrase: "studied as a potential treatment"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   781   C3161471:Treatment Study [Research Activity]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3245505:Potential [Qualitative Concept]
   760   C3538994:TREATMENT [Research Activity]
   726   C0557651:Study [Manufactured Object]
   726   C2603343:Study [Research Activity]

Phrase: "in mild cognitive impairment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1270972:Mild Cognitive Impairment [Mental or Behavioral Dysfunction]
   901   C0338656:Cognitive impairment [Mental or Behavioral Dysfunction]
   827   C0684336:Impairment [Pathologic Function]

Phrase: "a rational assumption as 55% of patients"

Phrase: "with this problem"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033213:Problem [Finding]

Phrase: "go on to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1822658:GO [Gene or Genome]

Phrase: "develop"

Phrase: "Alzheimer's disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "intervention here"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0886296:intervention [Health Care Activity]
   861   C1273869:Intervention [Health Care Activity]
   861   C1948041:Intervention [Therapeutic or Preventive Procedure]
   789 E C3274035:INTERVENTIONAL [Research Activity]

Phrase: "may"

Phrase: "have"

Phrase: "a profound effect on the burden of disease overall."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1280500:Effect [Qualitative Concept]
   742   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.86: No study of anticholinergic therapy in frontotemporal dementia is under way at present. 

Phrase: "No study of anticholinergic therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "in frontotemporal dementia"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0236642:frontotemporal dementia [Disease or Syndrome]
  1000   C0338451:Frontotemporal dementia [Disease or Syndrome]
   861   C0011265:dementia [Mental or Behavioral Dysfunction]
   861   C0497327:Dementia [Mental or Behavioral Dysfunction]
   761 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "is"

Phrase: "under way at present."
Processing 00000000.tx.87: Muscarinic agonists have been tried in Alzheimer's disease, but these drugs have a narrow therapeutic window before side-effects become intolerable, and to date no clinical trial has shown significant effects on cognition. 

Phrase: "Muscarinic agonists"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0242947:Muscarinic Agonists [Pharmacologic Substance]
   983 E C3536929:Muscarinic Agonist [Pharmacologic Substance]
   861   C0243192:agonists [Pharmacologic Substance]
   861   C2987634:agonists [Pharmacologic Substance]

Phrase: "have"

Phrase: "been"

Phrase: "tried in Alzheimer's disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "but"

Phrase: "these drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "have"

Phrase: "a narrow therapeutic window before side-effects"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   757   C1527144:Therapeutic Effect [Health Care Activity]
   748   C0039796:Therapeutic [Therapeutic or Preventive Procedure]
   748   C0302350:Therapeutic [Functional Concept]
   748   C0557702:Window [Manufactured Object]
   748   C1272706:Window [Temporal Concept]
   748   C1704674:Window [Manufactured Object]

Phrase: "become"

Phrase: "intolerable,"

Phrase: "and to date"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0011008:Date [Temporal Concept]
   790   C1515981:And [Idea or Concept]
   790   C2348077:Date [Food]

Phrase: "no clinical trial"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0008976:Clinical Trial [Research Activity]
           Trial
  1000   C1096775:Clinical Trial [Intellectual Product]
   861   C0205210:Clinical [Qualitative Concept]

Phrase: "has"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "significant effects on cognition."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.88: Nicotinic drugs are also still in early trial stages, with similar tolerability problems to overcome, but more promising efficacy data. 

Phrase: "Nicotinic drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are"

Phrase: "also still in early trial stages,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   790   C2986908:Trial Stages [Idea or Concept]
   783   C2363430:early stages [Temporal Concept]
   767 E C1517886:Early Stage [Classification]
   753   C0008976:Trial [Research Activity]
   753   C1279919:Early [Temporal Concept]
   753   C1306673:Stages [Qualitative Concept]
   719 E C0205390:Stage [Temporal Concept]
   719 E C1300072:Stage [Clinical Attribute]

Phrase: "with similar tolerability problems to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C1546466:Problems [Idea or Concept]
   779 E C0033213:Problem [Finding]

Phrase: "overcome"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2983310:Overcome [Activity]

Phrase: ","

Phrase: "but"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "promising"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1555307:promise [Idea or Concept]

Phrase: "efficacy data."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]
Processing 00000000.tx.89: NON-CHOLINERGIC DRUG THERAPY Research into Alzheimer's disease has led to understanding of some of the pathological mechanisms involved. 

Phrase: "NON-CHOLINERGIC DRUG THERAPY Research into Alzheimer's disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1515402:Therapy Research [Research Activity]
   744   C0035168:research [Research Activity]
   744   C0242481:Research [Research Activity]

Phrase: "has"

Phrase: "led to understanding of some of the pathological mechanisms"
Meta Candidates (Total=11; Excluded=6; Pruned=0; Remaining=5)
   742   C0030664:Pathological [Biomedical Occupation or Discipline]
   742   C0162340:Understanding [Mental Process]
   742   C0441712:Mechanisms [Functional Concept]
   742   C1521733:Pathological [Functional Concept]
   742   C1708698:LED [Manufactured Object]
   708 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   708 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   708 E C1522538:Lead [Functional Concept]
   708 E C1706376:Mechanism [Manufactured Object]
   708 E C2348269:Lead [Element, Ion, or Isotope]
   708 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "involved."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]
Processing 00000000.tx.90: Inflammation occurs, as evidenced by the inflammatory markers found  for example, complement attack complex at levels similar to those found in ischaemic heart disease (McGeer & McGeer, 1998). 

Phrase: "Inflammation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021368:Inflammation [Pathologic Function]

Phrase: "occurs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1709305:Occur [Activity]
  1000   C2745955:OCCUR [Temporal Concept]

Phrase: ","

Phrase: "as"

Phrase: "evidenced by the inflammatory markers"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0333348:Inflammatory [Functional Concept]
   726   C0005516:Marker [Clinical Attribute]
   726   C0332120:Evidence [Functional Concept]

Phrase: "found  for example,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0150312:Found [Quantitative Concept]
   790   C1707959:Example [Conceptual Entity]
   756 E C0243095:Find [Finding]

Phrase: "complement attack complex at levels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439855:Complex [Qualitative Concept]
   760   C1704241:Complex [Chemical Viewed Structurally]

Phrase: "similar to those"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "found in ischaemic heart disease"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   862   C0010054:ischaemic heart disease [Disease or Syndrome]
   862   C0151744:Ischaemic heart disease [Disease or Syndrome]
   862   C1313980:Ischemic heart disease [Finding]
   806   C0018799:Heart disease [Disease or Syndrome]
   760   C0012634:Disease [Disease or Syndrome]
   760   C0018787:Heart [Body Part, Organ, or Organ Component]
   760   C0150312:Found [Quantitative Concept]
   760   C0475224:Ischaemic [Functional Concept]
   760   C1281570:Heart [Body Part, Organ, or Organ Component]
   726 E C0243095:Find [Finding]
   704 E C1836721:MALS [Finding]
   704 E C3538764:MALS [Gene or Genome]
   704 E C3540595:MAL [Gene or Genome]

Phrase: "(McGeer & McGeer,"

Phrase: "1998"

Phrase: ")."
Processing 00000000.tx.91: Basic science coupled with the observation that sufferers from rheumatoid arthritis have a lower rate of Alzheimer's disease (Stewart et al, 1997) has led to trials of anti-inflammatory drugs in the treatment of Alzheimer's disease. 

Phrase: "Basic science"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681833:Basic Science [Research Activity]
   861   C0036397:Science [Occupation or Discipline]

Phrase: "coupled with the observation"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0302523:Observation [Research Activity]
   770   C0700325:observation [Health Care Activity]
   770   C1948027:Coupled [Functional Concept]
   770   C1964257:Observation [Diagnostic Procedure]
   737 E C0010222:couple [Family Group]

Phrase: "that sufferers from rheumatoid arthritis"

Phrase: "have"

Phrase: "a lower rate of Alzheimer's disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0026538:disease rate [Quantitative Concept]
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]

Phrase: "(Stewart et al,"

Phrase: "1997"

Phrase: ")"

Phrase: "has"

Phrase: "led to trials of anti-inflammatory drugs"
Meta Candidates (Total=14; Excluded=6; Pruned=0; Remaining=8)
   814   C0003209:anti inflammatory drugs [Pharmacologic Substance]
           Anti-inflammatory
   778   C1515999:Anti-inflammatory [Qualitative Concept]
   774   C0304229:drugs trials [Pharmacologic Substance]
   748   C0013227:Drugs [Pharmacologic Substance]
   748   C0333348:Inflammatory [Functional Concept]
   748   C1708698:LED [Manufactured Object]
   714   C0008976:Trial [Research Activity]
   714 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   714 E C1254351:Drug [Pharmacologic Substance]
   714 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   714 E C1522538:Lead [Functional Concept]
   714 E C2348269:Lead [Element, Ion, or Isotope]
   714 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in the treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "of Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.92: Trials with prednisolone have not been successful, but ongoing work with the cyclo-oxygenase inhibitors (especially Cox-2) in animal and now in human clinical trials may show benefit. 

Phrase: "Trials with prednisolone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C0008976:Trial [Research Activity]

Phrase: "have"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "successful,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1272703:Successful [Qualitative Concept]
   928 E C0597535:Success [Social Behavior]

Phrase: "but"

Phrase: "ongoing work with the cyclo-oxygenase inhibitors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0043227:Work [Occupational Activity]

Phrase: "(especially Cox-2) in animal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1565860:COX-2 [Amino Acid, Peptide, or Protein,Enzyme]
   806   C1705323:COX-2 [Gene or Genome]

Phrase: "and"

Phrase: "now in human clinical trials"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0008976:Clinical Trials [Research Activity]
           Trial
   806   C1096775:clinical trials [Intellectual Product]
   760   C0086418:Human [Human]
   760   C0205210:Clinical [Qualitative Concept]
   760   C1948052:Now [Temporal Concept]

Phrase: "may"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "benefit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0814225:Benefit [Quantitative Concept]
Processing 00000000.tx.93: These drugs are not without long-term side-effects, so current practice is not to recommend their use routinely. 

Phrase: "These drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are"

Phrase: "not without long-term side-effects,"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   820   C0023983:Long-Term Effects [Phenomenon or Process]
   790   C0001688:side effects [Functional Concept]
   790   C0443252:Long-term [Temporal Concept]
   756 E C0879626:Side Effect [Pathologic Function]
   753   C0205166:Long [Qualitative Concept]
   753   C0441987:Side [Spatial Concept]
   753   C1280500:effects [Qualitative Concept]
   753   C1515273:Term [Temporal Concept]
   753   C1518422:Not [Functional Concept]
   753   C1705313:Term [Idea or Concept]
   753   C1706317:Long [Qualitative Concept]
   753   C2826302:TERM [Intellectual Product]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "so"

Phrase: "current practice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0237607:practice [Mental Process]
   861   C3245512:practice [Intellectual Product]

Phrase: "is"

Phrase: "not to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "recommend"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034866:recommend [Idea or Concept]

Phrase: "their use routinely."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0042153:use [Functional Concept]
   861   C0457083:Use [Functional Concept]
   861   C1947944:Use [Intellectual Product]
Processing 00000000.tx.94: Another observational study has shown that women on hormone replacement therapy (HRT) have a reduced rate of Alzheimer's disease (Robinson et al, 1994). 

Phrase: "Another observational study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1518527:Observational Study [Research Activity]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "has"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that women on hormone replacement therapy (HRT)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0043210:Women [Population Group]

Phrase: "have"

Phrase: "a reduced rate of Alzheimer's disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0026538:disease rate [Quantitative Concept]
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]

Phrase: "(Robinson et al,"

Phrase: "1994"

Phrase: ")."
Processing 00000000.tx.95: The protective effect of oestrogen on the nervous system and its vasculature is well-documented (Birge, 1997), so clinical trials are now in progress to test the efficacy of oestrogen therapy (17-oestradiol particularly). 

Phrase: "The protective effect of oestrogen"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0877035:Estrogen Effect [Finding]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on the nervous system"
Meta Candidates (Total=15; Excluded=7; Pruned=0; Remaining=8)
  1000   C0027763:Nervous System [Body System]
  1000   C0422837:NERVOUS SYSTEM [Finding]
  1000   C1269560:Nervous system [Body System]
   944 E C0205494:Neurologic [Qualitative Concept]
   907 E C0027855:Neurology [Biomedical Occupation or Discipline]
   888 E C2707261:Neurological [Clinical Attribute]
   861   C0027769:Nervous [Sign or Symptom]
   861   C0449913:System [Functional Concept]
   861   C0599851:Nervous [Functional Concept]
   861   C1553451:System [Manufactured Object]
   861   C1704459:System [Medical Device]
   789 E C0205373:Systemic [Functional Concept]
   745 E C0027740:Nerve [Tissue]
   745 E C0027757:NERVE [Tissue]
   745 E C1280541:Nerve [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "its vasculature"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005839:vasculature [Body Part, Organ, or Organ Component]

Phrase: "is"

Phrase: "well-documented"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0205170:Well [Qualitative Concept]
   861   C1301725:Documented [Health Care Activity]
   861   C1609436:documented [Idea or Concept]
   861   C3146287:Well [Manufactured Object]
   827 E C1301746:document [Intellectual Product]
   827 E C1547673:Document [Intellectual Product]

Phrase: "(Birge,"

Phrase: "1997"

Phrase: ")"

Phrase: ","

Phrase: "so"

Phrase: "clinical trials"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0008976:Clinical Trials [Research Activity]
           Trial
  1000   C1096775:clinical trials [Intellectual Product]
   861   C0205210:Clinical [Qualitative Concept]

Phrase: "are"

Phrase: "now in progress to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1272688:progress [Functional Concept]
   812   C1280477:Progress [Functional Concept]
   812   C1948052:Now [Temporal Concept]

Phrase: "test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022885:Test [Laboratory Procedure]
  1000   C0039593:Test [Functional Concept]
  1000   C0392366:test [Intellectual Product]

Phrase: "the efficacy of oestrogen therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280519:Efficacy [Qualitative Concept]
   760   C1707887:EFFICACY [Research Activity]

Phrase: "(17-oestradiol particularly"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0014912:Estradiol [Hormone,Pharmacologic Substance,Steroid]
   771 E C0699352:Estrace [Hormone,Pharmacologic Substance,Steroid]
   771 E C0878472:Progynon [Hormone,Pharmacologic Substance,Steroid]

Phrase: ")."
Processing 00000000.tx.96: Early treatment study results are not encouraging (Mulnard et al, 2000), so again, in the absence of published positive studies, HRT cannot be recommended for use as a treatment in Alzheimer's disease  although it does seem that its use is increasing in Alzheimer's disease prophylaxis, particularly in the USA. 

Phrase: "Early treatment study results"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0683954:study results [Finding]
   861   C3161471:Treatment Study [Research Activity]
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]
   779   C1274040:Result [Functional Concept]
   779   C1546471:Result [Idea or Concept]
   779   C2825142:Result [Finding]

Phrase: "are"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "encouraging"

Phrase: "(Mulnard et al,"

Phrase: "2000"

Phrase: ")"

Phrase: ","

Phrase: "so"

Phrase: "again,"

Phrase: "in the absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "of published positive studies,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "HRT"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
  1000   C0282402:Hormone replacement therapy [Therapeutic or Preventive Procedure]
           hormone replacement
   913   C0279025:Hormone Therapy [Therapeutic or Preventive Procedure]
   901   C0279033:Replacement therapy [Therapeutic or Preventive Procedure]
   827   C0019932:Hormone [Hormone]
   827   C0035139:Replacement [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C0559956:Replacement [Functional Concept]
   827   C1363945:Therapy [Finding]
   827   C1555302:Replacement [Idea or Concept]
   755 E C0458083:Hormonal [Qualitative Concept]

Phrase: "cannot"

Phrase: "be"

Phrase: "recommended for use"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0034866:Recommended [Idea or Concept]
   790   C0042153:use [Functional Concept]
   790   C0457083:Use [Functional Concept]
   790   C1947944:Use [Intellectual Product]

Phrase: "as a treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "in Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "although"

Phrase: "it"

Phrase: "does"

Phrase: "seem"

Phrase: "that"

Phrase: "its use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "is"

Phrase: "increasing in Alzheimer's disease prophylaxis,"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   806   C0002395:Alzheimer's Disease [Disease or Syndrome]
   806   C1521724:Alzheimer's Disease [Pathologic Function]
   760   C0012634:Disease [Disease or Syndrome]
   760   C0033107:prophylaxis [Intellectual Product]
   760   C0199176:Prophylaxis [Therapeutic or Preventive Procedure]
   760   C0442808:Increasing [Functional Concept]
   751   C0277564:Acquired disease [Disease or Syndrome]
   726 E C0442805:Increase [Functional Concept]
   704 E C1836721:MALS [Finding]
   704 E C3538764:MALS [Gene or Genome]
   704 E C3540595:MAL [Gene or Genome]

Phrase: "particularly in the USA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0041703:USA [Geographic Area]
Processing 00000000.tx.97: Antioxidants have shown benefit in several areas of chronic ill health, including Alzheimer's disease, after a study of selegiline and vitamin E and their effect on disease progression (Sano et al, 1997). 

Phrase: "Antioxidants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003402:Antioxidants [Pharmacologic Substance]

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "benefit in several areas of chronic ill health,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   767   C0086387:Health Benefit [Quantitative Concept]
   744   C0018684:Health [Idea or Concept]
   744   C0205146:areas [Spatial Concept]
   744   C0205191:chronic [Temporal Concept]
   744   C0231218:Ill [Sign or Symptom]
   744   C0814225:Benefit [Quantitative Concept]
   711 E C0017446:Area [Geographic Area]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "Alzheimer's disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "after"

Phrase: "a study of selegiline"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "vitamin E"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042874:Vitamin E [Lipid,Pharmacologic Substance,Vitamin]
   944 E C0591450:Ephynal [Organic Chemical,Pharmacologic Substance,Vitamin]
   861   C0042890:Vitamin [Organic Chemical,Pharmacologic Substance,Vitamin]

Phrase: "and"

Phrase: "their effect on disease progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "(Sano et al,"

Phrase: "1997"

Phrase: ")."
Processing 00000000.tx.98: This showed a positive effect on the rate of increasing dependency and delayed institutionalisation. 

Phrase: "This"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a positive effect on the rate of increasing dependency"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1280500:Effect [Qualitative Concept]
   742   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "delayed institutionalisation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021629:Institutionalization [Health Care Activity]
Processing 00000000.tx.99: However, this has yet to be replicated. 

Phrase: "However,"

Phrase: "this"

Phrase: "has"

Phrase: "yet to"

Phrase: "be"

Phrase: "replicated."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205173:replicated [Functional Concept]
   966 E C0205341:Replicate [Functional Concept]
   966 E C1883725:Replicate [Qualitative Concept]
Processing 00000000.tx.100: Vitamin E is inexpensive and relatively safe  the trial was high dosage (2000 IU). 

Phrase: "Vitamin E"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042874:Vitamin E [Lipid,Pharmacologic Substance,Vitamin]
   944 E C0591450:Ephynal [Organic Chemical,Pharmacologic Substance,Vitamin]
   861   C0042890:Vitamin [Organic Chemical,Pharmacologic Substance,Vitamin]

Phrase: "is"

Phrase: "inexpensive"

Phrase: "and"

Phrase: "relatively safe"

Phrase: "the trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0008976:Trial [Research Activity]

Phrase: "was"

Phrase: "high dosage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0178602:Dosage [Quantitative Concept]

Phrase: "(2000 IU"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439453:IU [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.101: Institutionalisation is expensive, so the return on this treatment is potentially high  but not rigorously proven. 

Phrase: "Institutionalisation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021629:Institutionalization [Health Care Activity]

Phrase: "is"

Phrase: "expensive,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0680864:expense [Quantitative Concept]

Phrase: "so"

Phrase: "the return on this treatment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332156:Return [Qualitative Concept]

Phrase: "is"

Phrase: "potentially high"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205250:High [Qualitative Concept]
   861   C1299351:High [Qualitative Concept]
   861   C2700149:HIGH [Intellectual Product]

Phrase: "but"

Phrase: "not rigorously"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "proven."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456369:Proven [Qualitative Concept]
Processing 00000000.tx.102: Many clinics are now routinely suggesting the use of vitamin E to patients with Alzheimer's disease  usually at about 1000 IU. 

Phrase: "Many clinics"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0442592:clinics [Health Care Related Organization,Manufactured Object]
   966 E C0002424:Clinic [Health Care Related Organization,Manufactured Object]
   916 E C0205210:Clinical [Qualitative Concept]

Phrase: "are"

Phrase: "now routinely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1948052:Now [Temporal Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "the use of vitamin E"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "to patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with Alzheimer's disease  usually"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0002395:Alzheimer's Disease [Disease or Syndrome]
   901   C1521724:Alzheimer's Disease [Pathologic Function]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "at about 1000 IU."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439453:IU [Quantitative Concept]
Processing 00000000.tx.103: It is possible that this may benefit other dementias and neurodegenerative disease as well. 

Phrase: "It"

Phrase: "is"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that"

Phrase: "this"

Phrase: "may"

Phrase: "benefit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0814225:Benefit [Quantitative Concept]

Phrase: "other dementias"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0497327:Dementias [Mental or Behavioral Dysfunction]
   966 E C0011265:dementia [Mental or Behavioral Dysfunction]
   893 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "and"

Phrase: "neurodegenerative disease as well."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   833   C0524851:Neurodegenerative Disease [Disease or Syndrome]
   770   C0012634:Disease [Disease or Syndrome]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.104: Nootropic drugs are available for prescription in Germany  the best-known being Gingko biloba extract, nicergoline and piracetam. 

Phrase: "Nootropic drugs"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0242913:Nootropic Drugs [Pharmacologic Substance]
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are"

Phrase: "available for prescription"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0470187:Available [Functional Concept]

Phrase: "in Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: "the best-known"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0205309:Known [Qualitative Concept]
   861   C1522427:Best [Qualitative Concept]
   827 E C0205170:Well [Qualitative Concept]
   827 E C3146287:Well [Manufactured Object]

Phrase: "being"

Phrase: "Gingko biloba extract,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0772125:Ginkgo biloba extract [Organic Chemical,Pharmacologic Substance]
           Ginkgo Extract
           Ginkgo biloba
   827   C2828366:Extract [Substance]
   734   C0330206:Gingko biloba [Plant]
   734   C3531686:Ginkgo biloba [Organic Chemical,Pharmacologic Substance]

Phrase: "nicergoline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0028008:Nicergoline [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "piracetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031977:Piracetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.105: Precise modes of action are unclear, yet they do seem to produce an effect in some well-controlled studies. 

Phrase: "Precise modes of action"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   898   C1524059:mode of action [Functional Concept]
   737   C1513371:Mode [Functional Concept]
   737   C1705738:Mode [Quantitative Concept]
   737   C2347637:Mode [Quantitative Concept]
   737   C2348146:Mode [Quantitative Concept]

Phrase: "are"

Phrase: "unclear, yet"

Phrase: "they"

Phrase: "do"

Phrase: "seem"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "produce"

Phrase: "an effect in some well-controlled studies."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.106: Glutamate is increasingly implicated in dementia pathogenesis, with N-methyl-D-aspartate (NMDA) blockade a putative therapy. 

Phrase: "Glutamate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017789:glutamate [Amino Acid, Peptide, or Protein]
  1000   C0220839:Glutamate [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "is"

Phrase: "increasingly"

Phrase: "implicated in dementia pathogenesis,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0011265:dementia [Mental or Behavioral Dysfunction]
   770   C0497327:Dementia [Mental or Behavioral Dysfunction]
   770   C0543483:pathogenesis [Functional Concept]
   770   C0699748:Pathogenesis [Pathologic Function]

Phrase: "with N-methyl-D-aspartate (NMDA) blockade"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0085845:Aspartate [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0332206:Blockade [Functional Concept]
   799   C0332287:With [Qualitative Concept]
   799   C1705690:With [Intellectual Product]
   799   C3540676:Blockade [Pharmacologic Substance]

Phrase: "a putative therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.107: Memantine, an NMDA blocker, has had positive results reported in severe Alzheimer's disease (e.g. Winblad & Poritis, 1999), leading to application for regulatory approval for its use in dementia. 

Phrase: "Memantine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025242:Memantine [Organic Chemical,Pharmacologic Substance]

Phrase: "an NMDA blocker,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0085845:Aspartate [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "has"

Phrase: "had"

Phrase: "positive results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "reported in severe Alzheimer's disease"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   806   C0002395:Alzheimer's Disease [Disease or Syndrome]
   806   C1521724:Alzheimer's Disease [Pathologic Function]
   760   C0012634:Disease [Disease or Syndrome]
   760   C0205082:Severe [Qualitative Concept]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]
   704 E C1836721:MALS [Finding]
   704 E C3538764:MALS [Gene or Genome]
   704 E C3540595:MAL [Gene or Genome]

Phrase: "("

Phrase: "e.g. Winblad & Poritis,"

Phrase: "1999"

Phrase: ")"

Phrase: ","

Phrase: "leading to application"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   790   C0185125:Application [Health Care Activity]
   790   C0332152:Leading [Temporal Concept]
   790   C1522538:Leading [Functional Concept]
   790   C1947919:Application [Intellectual Product]
   790   C2347934:Application [Intellectual Product]
   790   C3539080:APPLICATION [Quantitative Concept]
   756 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   756 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   756 E C2348269:Lead [Element, Ion, or Isotope]
   756 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "for regulatory approval"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205540:Approval [Qualitative Concept]
   861   C2346845:Approval [Intellectual Product]

Phrase: "for its use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "in dementia."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0011265:dementia [Mental or Behavioral Dysfunction]
  1000   C0497327:Dementia [Mental or Behavioral Dysfunction]
   900 E C0860630:dement [Mental or Behavioral Dysfunction]
Processing 00000000.tx.108: Nerve cell destruction seems secondary to activation of glial cells, so stabilisation of these glial cells may reduce the rate of Alzheimer's disease and other dementias. 

Phrase: "Nerve cell destruction"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0196878:nerve destruction [Therapeutic or Preventive Procedure]
   827   C1261381:Destruction [Therapeutic or Preventive Procedure]
   827   C1948029:Destruction [Activity]
   734   C0027882:Nerve cell [Cell]

Phrase: "seems"

Phrase: "secondary to activation of glial cells,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0175668:Secondary to [Temporal Concept]
           Secondary
   753   C0027627:secondary [Neoplastic Process]
   753   C0205436:Secondary [Quantitative Concept]

Phrase: "so"

Phrase: "stabilisation of these glial cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1293130:Stabilisation [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "reduce"

Phrase: "the rate of Alzheimer's disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0026538:disease rate [Quantitative Concept]
   760   C0871208:Rate [Activity]
   760   C1521828:Rate [Quantitative Concept]

Phrase: "and"

Phrase: "other dementias."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0497327:Dementias [Mental or Behavioral Dysfunction]
   966 E C0011265:dementia [Mental or Behavioral Dysfunction]
   893 E C0860630:dement [Mental or Behavioral Dysfunction]
Processing 00000000.tx.109: Several compounds such as propentofylline purportedly have this effect, especially in vitro, but to date have shown no therapeutic effect clinically. 

Phrase: "Several compounds such as propentofylline purportedly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0205198:Compound [Qualitative Concept]
   719   C1706082:Compound [Chemical]

Phrase: "have"

Phrase: "this effect,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "especially in vitro,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0021135:In Vitro [Intellectual Product]
   901   C1533691:in vitro [Qualitative Concept]
           vitro
   901   C2827718:In Vitro [Functional Concept]

Phrase: "but to date"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0011008:Date [Temporal Concept]
   790   C0233535:but [Mental or Behavioral Dysfunction]
   790   C2348077:Date [Food]

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no therapeutic effect clinically."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1527144:Therapeutic Effect [Health Care Activity]
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.110: It remains a potential area of research. 

Phrase: "It"

Phrase: "remains"

Phrase: "a potential area of research."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017446:Area [Geographic Area]
   760   C0205146:Area [Spatial Concept]
Processing 00000000.tx.111: The cortical cholinergic system is diffusely spread and a long way from its cell bodies. 

Phrase: "The cortical cholinergic system"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0684164:cholinergic system [Biologically Active Substance]
   827   C0449913:System [Functional Concept]
   827   C1553451:System [Manufactured Object]
   827   C1704459:System [Medical Device]
   755 E C0205373:Systemic [Functional Concept]

Phrase: "is"

Phrase: "diffusely"

Phrase: "spread"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332261:Spread [Qualitative Concept]
  1000   C1947932:Spread [Activity]

Phrase: "and"

Phrase: "a long way from its cell bodies."
Processing 00000000.tx.112: It is therefore dependent on nerve growth factor (NGF) to sustain it, and a reduction in NGF may be associated with Alzheimer's disease. 

Phrase: "It"

Phrase: "is"

Phrase: "therefore dependent on nerve growth factor (NGF) to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0851827:Dependent [Qualitative Concept]
   748   C1701901:Dependent [Qualitative Concept]
   748   C3244310:dependent [Functional Concept]

Phrase: "sustain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443318:sustain [Functional Concept]
  1000   C2732140:Sustain [Organic Chemical,Pharmacologic Substance]

Phrase: "it,"

Phrase: "and"

Phrase: "a reduction in NGF"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "be"

Phrase: "associated with Alzheimer's disease."
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   819   C0243083:associated disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.113: Studies injecting NGF by cannulae into the cerebrospinal fluid showed some effect, but this is not a practical solution. 

Phrase: "Studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "injecting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1720154:Inject [Functional Concept]

Phrase: "NGF by cannulae"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   862   C0027752:Nerve Growth Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   862   C0027754:Nerve growth factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   862   C1522443:Nerve Growth Factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   806   C0018284:Growth Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   778   C0814002:Neural Growth [Cell Function,Organism Function]
   760   C0018270:'growth' NOS [Organism Function]
   760   C0027740:Nerve [Tissue]
   760   C0027757:NERVE [Tissue]
   760   C0220844:growth [Physiologic Function]
   760   C1280541:Nerve [Body Part, Organ, or Organ Component]
   760   C1521761:Factor [Functional Concept]
   760   C1621966:Growth [Organ or Tissue Function]
   760   C2827422:Factor [Conceptual Entity]
   760   C2911660:Growth [Activity]
   704 E C0599851:Neural [Functional Concept]

Phrase: "into the cerebrospinal fluid"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0007806:Cerebrospinal Fluid [Body Substance]
  1000   C0007807:cerebrospinal fluid [Functional Concept]
   861   C0005889:FLUID [Body Substance]
   861   C0302908:fluid [Substance]
   861   C0444611:Fluid [Qualitative Concept]
   861   C1704353:Fluid [Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "some effect,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "but"

Phrase: "this"

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "a practical solution."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037633:Solution [Substance]
   861   C0525069:Solution [Biomedical or Dental Material]
Processing 00000000.tx.114: Attempts to formulate the active portion of NGF into an oral preparation that crosses the bloodbrain barrier are ongoing; 

Phrase: "Attempts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516084:Attempt [Event]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "formulate"

Phrase: "the active portion of NGF"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0449719:Portion [Spatial Concept]

Phrase: "into an oral preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0455052:Preparation [Health Care Activity]
   861   C1521827:Preparation [Functional Concept]

Phrase: "that"

Phrase: "crosses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2828360:Cross [Conceptual Entity]

Phrase: "the bloodbrain barrier"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005854:Blood-Brain Barrier [Body Part, Organ, or Organ Component]
  1000   C1305865:Blood-brain barrier [Organ or Tissue Function]
   861   C1706912:BARRIER [Medical Device]

Phrase: "are"

Phrase: "ongoing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:ONGOING [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.115: meanwhile a xanthine derivative (leteprinim potassium) that seems to have a stimulating effect on NGF is about to start clinical trial. 

Phrase: "meanwhile"

Phrase: "a xanthine derivative"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1527240:Derivative [Functional Concept]

Phrase: "(leteprinim potassium"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1450638:leteprinim potassium [Organic Chemical,Pharmacologic Substance]
   861   C0032821:Potassium [Element, Ion, or Isotope]
   861   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: ")"

Phrase: "that"

Phrase: "seems"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "a stimulating effect on NGF"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "about to"

Phrase: "start"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439659:Start [Temporal Concept]

Phrase: "clinical trial."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0008976:Clinical Trial [Research Activity]
           Trial
  1000   C1096775:Clinical Trial [Intellectual Product]
   861   C0205210:Clinical [Qualitative Concept]
Processing 00000000.tx.116: WHAT OF PLAQUES AND TANGLES? 

Phrase: "WHAT OF PLAQUES"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0333463:plaques [Acquired Abnormality]
   756 E C0011389:Plaque [Disease or Syndrome]
   756 E C0332461:Plaque [Finding]

Phrase: "AND"

Phrase: "TANGLES?"
Processing 00000000.tx.117: The pathological basis of Alzheimer's disease is the presence of amyloid plaques and neurofibrillary tangles. 

Phrase: "The pathological basis of Alzheimer's disease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]

Phrase: "is"

Phrase: "the presence of amyloid plaques"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "neurofibrillary tangles."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0085400:Neurofibrillary Tangles [Acquired Abnormality]
   966 E C3543859:neurofibrillary tangle [Cell Component]
Processing 00000000.tx.118: Most work has focused on the amyloid cascade that produces the plaques, and various drugs are in development to modify amyloid metabolism. 

Phrase: "Most work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "has"

Phrase: "focused on the amyloid"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0002716:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0011560:Amyloid [Pathologic Function]
   770   C0205234:Focused [Spatial Concept]
   770   C0611285:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1285542:focused [Functional Concept]

Phrase: "cascade"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707310:Cascade [Manufactured Object]

Phrase: "that"

Phrase: "produces"

Phrase: "the plaques,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0333463:plaques [Acquired Abnormality]
   966 E C0011389:Plaque [Disease or Syndrome]
   966 E C0332461:Plaque [Finding]

Phrase: "and"

Phrase: "various drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are in development to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0243107:development [Physiologic Function]
   770   C0678723:Development [Organism Function]
   770   C1527148:Development [Functional Concept]
   770   C1551058:Are [Quantitative Concept]

Phrase: "modify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:MODIFY [Functional Concept]

Phrase: "amyloid metabolism."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]
Processing 00000000.tx.119: The most imminent clinical trial is the injection of beta-amyloid protein to vaccinate the individual and produce an antibody response that might remove amyloid from the nervous tissue. 

Phrase: "The most imminent clinical trial"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0008976:Clinical Trial [Research Activity]
           Trial
   861   C1096775:Clinical Trial [Intellectual Product]
   812   C0205210:Clinical [Qualitative Concept]

Phrase: "is"

Phrase: "the injection of beta-amyloid protein to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0021485:injection [Therapeutic or Preventive Procedure]
   748   C1272883:Injection [Biomedical or Dental Material]
   748   C1533685:Injection [Therapeutic or Preventive Procedure]
   748   C1828121:Injection [Functional Concept]

Phrase: "vaccinate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1116171:vaccinate [Finding]

Phrase: "the individual"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027361:Individual [Population Group]
  1000   C0237401:Individual [Human]

Phrase: "and"

Phrase: "produce"

Phrase: "an antibody response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0003261:Antibody Response [Biologic Function]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "that"

Phrase: "might"

Phrase: "remove"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0849355:remove [Qualitative Concept]
  1000   C1883720:Remove [Activity]
  1000   C3244314:remove [Functional Concept]

Phrase: "amyloid from the nervous tissue."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002716:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0011560:Amyloid [Pathologic Function]
   760   C0611285:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.120: In mice this procedure relieved symptoms in genetic Alzheimer's disease animal models (Schenk et al, 1999) and prevented plaque formation in younger mice. 

Phrase: "In mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "this procedure relieved symptoms in genetic Alzheimer's disease animal models"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0683368:symptoms [Functional Concept]
   739   C1457887:Symptoms [Sign or Symptom]

Phrase: "(Schenk et al,"

Phrase: "1999"

Phrase: ")"

Phrase: "and"

Phrase: "prevented plaque formation in younger mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0220781:formation [Biologic Function]
   753   C0439634:formation [Spatial Concept]
   753   C1522492:Formation [Functional Concept]
Processing 00000000.tx.121: This method is being tried in humans in both the UK and the USA, and represents the first true attempt at disease modification. 

Phrase: "This method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025663:Method [Intellectual Product]
  1000   C0449851:Method [Functional Concept]
  1000   C0871511:METHOD [Intellectual Product]

Phrase: "is"

Phrase: "being"

Phrase: "tried in humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0086418:Humans [Human]

Phrase: "in both"

Phrase: "the UK"

Phrase: "and"

Phrase: "the USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "and"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the first true attempt at disease modification."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1516084:Attempt [Event]
Processing 00000000.tx.122: The other classical pathological change is the development of tangles, made up of abnormal tau protein. 

Phrase: "The"

Phrase: "other classical pathological change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0392747:Change [Functional Concept]
   827   C0443172:change [Quantitative Concept]
   827   C1705241:Change [Quantitative Concept]

Phrase: "is"

Phrase: "the development of tangles,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0243107:development [Physiologic Function]
   770   C0678723:Development [Organism Function]
   770   C1527148:Development [Functional Concept]

Phrase: "made up of abnormal tau protein."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1881534:Make [Functional Concept]
Processing 00000000.tx.123: Tau pathology is known to exist in other neurodegenerative conditions and is an important area of research in treating other dementing diseases such as frontotemporal dementia and progressive supranuclear palsy. 

Phrase: "Tau pathology"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0030664:Pathology [Biomedical Occupation or Discipline]
   861   C0205469:pathology [Functional Concept]
   861   C0677042:pathology [Pathologic Function]
   789 E C1521733:Pathologic [Functional Concept]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "exist in other neurodegenerative conditions"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C2987476:Exist [Conceptual Entity]
   726   C0012634:condition [Disease or Syndrome]
   726   C0348080:Condition [Qualitative Concept]
   726   C1705253:Condition [Conceptual Entity]

Phrase: "and"

Phrase: "is"

Phrase: "an important area of research"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017446:Area [Geographic Area]
   760   C0205146:Area [Spatial Concept]

Phrase: "in treating"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treating [Therapeutic or Preventive Procedure]
  1000   C1522326:Treating [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "other dementing diseases such as frontotemporal dementia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0012634:Diseases [Disease or Syndrome]

Phrase: "and"

Phrase: "progressive supranuclear palsy."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0038868:Progressive supranuclear palsy [Disease or Syndrome]
   901   C0270920:Supranuclear palsy [Disease or Syndrome]
   885   C0205858:PARALYSIS, PROGRESSIVE [Disease or Syndrome]
   827   C0205329:Progressive [Functional Concept]
   827   C0522224:Palsy [Finding]
Processing 00000000.tx.124: The hyperphosphorylation that occurs in Alzheimer's disease may be amenable to therapeutic intervention, and while there are some experimental models now to support this, no drugs are in clinical trials as yet. 

Phrase: "The hyperphosphorylation"

Phrase: "that"

Phrase: "occurs in Alzheimer's disease"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   770   C1709305:Occur [Activity]
   770   C2745955:OCCUR [Temporal Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "amenable to therapeutic intervention,"

Phrase: "and"

Phrase: "while"

Phrase: "there"

Phrase: "are"

Phrase: "some experimental models now to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0086272:Models, Experimental [Intellectual Product]
   812   C1517586:Experimental [Qualitative Concept]
   812   C1948052:Now [Temporal Concept]
   812   C3161035:Models [Intellectual Product]

Phrase: "support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "this,"

Phrase: "no drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "are in clinical trials"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0008976:Clinical Trials [Research Activity]
           Trial
   833   C1096775:clinical trials [Intellectual Product]
   770   C0205210:Clinical [Qualitative Concept]
   770   C1551058:Are [Quantitative Concept]

Phrase: "as yet."
Processing 00000000.tx.125: FUTURE CHALLENGES Basic science research is gradually unlocking some of the pathological sequences in dementia (especially in Alzheimer's disease) to provide theoretical treatment opportunities. 

Phrase: "FUTURE"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016884:Future [Temporal Concept]

Phrase: "CHALLENGES"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0798503:Challenge [Clinical Attribute]
  1000   C0805586:Challenge [Health Care Activity]
  1000   C3274764:Challenge [Conceptual Entity]

Phrase: "Basic science research"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0681833:Basic Science Research [Research Activity]
           Basic Research
           Basic Science
   827   C0035168:research [Research Activity]
   827   C0242481:Research [Research Activity]

Phrase: "is"

Phrase: "gradually"

Phrase: "unlocking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1550031:Unlock [Idea or Concept]

Phrase: "some of the pathological sequences"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0030664:Pathological [Biomedical Occupation or Discipline]
   760   C0162326:Sequences [Nucleotide Sequence]
   760   C0205392:Some [Quantitative Concept]
   760   C1521733:Pathological [Functional Concept]
   760   C3540770:Some [Intellectual Product]
   726 E C0004793:Sequence [Nucleotide Sequence]
   726 E C0162327:Sequence [Nucleotide Sequence]
   726 E C1519249:Sequence [Functional Concept]

Phrase: "in dementia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0011265:dementia [Mental or Behavioral Dysfunction]
  1000   C0497327:Dementia [Mental or Behavioral Dysfunction]
   900 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "(especially in Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "theoretical treatment opportunities."
Processing 00000000.tx.126: This began with the AChEIs and is now at the stage of amyloid modification. 

Phrase: "This"

Phrase: "began with the AChEIs"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   806   C0001046:Acetylcholinesterase Inhibitors [Pharmacologic Substance]
   790 E C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   760   C0001044:Acetylcholine esterase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0243077:inhibitors [Chemical Viewed Functionally]
   726   C0439659:Begin [Temporal Concept]
   726 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "and"

Phrase: "is"

Phrase: "now at the stage of amyloid modification."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   748   C0002716:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0011560:Amyloid [Pathologic Function]
   748   C0205390:Stage [Temporal Concept]
   748   C0392747:Modification [Functional Concept]
   748   C0611285:Amyloid [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C1300072:Stage [Clinical Attribute]
   748   C1306673:Stage [Qualitative Concept]
   748   C1554963:modification [Qualitative Concept]
   748   C1948052:Now [Temporal Concept]
Processing 00000000.tx.127: For the first time therapeutic options exist in Alzheimer's disease and will soon be available in other dementias. 

Phrase: "For the first time therapeutic options"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C1518601:Options [Functional Concept]
   779 E C1550456:option [Idea or Concept]
   729 E C1518600:Optional [Qualitative Concept]

Phrase: "exist in Alzheimer's disease"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   770   C2987476:Exist [Conceptual Entity]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "will"

Phrase: "soon"

Phrase: "be"

Phrase: "available in other dementias."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0470187:Available [Functional Concept]
Processing 00000000.tx.128: These may be as simple as using vitamin E, through to combinations of therapy to maximise benefit (Table 2). 

Phrase: "These"

Phrase: "may"

Phrase: "be"

Phrase: "as"

Phrase: "simple"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205352:Simple [Qualitative Concept]

Phrase: "as"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "vitamin E,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042874:Vitamin E [Lipid,Pharmacologic Substance,Vitamin]
   944 E C0591450:Ephynal [Organic Chemical,Pharmacologic Substance,Vitamin]
   861   C0042890:Vitamin [Organic Chemical,Pharmacologic Substance,Vitamin]

Phrase: "through"

Phrase: "to combinations"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0453882:Combinations [Manufactured Object]
   966 E C0205195:Combination [Qualitative Concept]
   966 E C1947911:Combination [Physical Object]

Phrase: "of therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "to"

Phrase: "maximise"

Phrase: "benefit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0814225:Benefit [Quantitative Concept]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.129: Although these treatments are still predominantly symptomatic, they offer relief to patients and have increased clinicians' awareness of the condition. 

Phrase: "Although"

Phrase: "these treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "are"

Phrase: "still predominantly symptomatic,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0231220:Symptomatic [Functional Concept]

Phrase: "they"

Phrase: "offer"

Phrase: "relief to patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0564405:Relief [Finding]

Phrase: "and"

Phrase: "have"

Phrase: "increased clinicians' awareness of the condition."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0004448:Awareness [Mental Process]
Processing 00000000.tx.130: This has taken old age psychiatry from its roots in social psychiatry to a point at which psychopharmacology has an important role. 

Phrase: "This"

Phrase: "has"

Phrase: "taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "old age psychiatry from its roots"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1273857:Old age psychiatry [Biomedical Occupation or Discipline]
   753   C0033872:Psychiatry [Professional or Occupational Group]
   753   C0033873:Psychiatry [Biomedical Occupation or Discipline]

Phrase: "in social psychiatry"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0086994:Social Psychiatry [Biomedical Occupation or Discipline]
   861   C0033872:Psychiatry [Professional or Occupational Group]
   861   C0033873:Psychiatry [Biomedical Occupation or Discipline]
   861   C0728831:Social [Functional Concept]
   789 E C0205487:Psychiatric [Functional Concept]

Phrase: "to a point"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552961:Point [Quantitative Concept]
  1000   C2347617:point [Quantitative Concept]

Phrase: "at which psychopharmacology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033929:Psychopharmacology [Biomedical Occupation or Discipline]

Phrase: "has"

Phrase: "an important role."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035820:Role [Social Behavior]
   861   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.131: The challenge now is to learn how to use these treatments most effectively. 

Phrase: "The challenge now"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0798503:Challenge [Clinical Attribute]
   861   C0805586:Challenge [Health Care Activity]
   861   C3274764:Challenge [Conceptual Entity]

Phrase: "is"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "learn"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023185:learn [Mental Process]

Phrase: "how to"

Phrase: "use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "these treatments most effectively."
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0087111:Treatments [Therapeutic or Preventive Procedure]
   793 E C0039798:treatment [Functional Concept]
   793 E C1522326:Treatment [Functional Concept]
   793 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   793 E C1705169:Treatment [Conceptual Entity]
   793 E C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.132: This means that everyone in the speciality who uses these treatments has the opportunity to contribute to the debate, and the prospects of development over the next 10 years make this one of the most exciting and dynamic areas of medicine in which to work. 

Phrase: "This means"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1704970:Means [Conceptual Entity]
   966 E C0444504:Mean [Quantitative Concept]
   966 E C2347634:Mean [Quantitative Concept]
   966 E C2348143:Mean [Quantitative Concept]

Phrase: "that"

Phrase: "everyone in the speciality"

Phrase: "who"

Phrase: "uses"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "these treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "has"

Phrase: "the opportunity to"

Phrase: "contribute to the debate,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0870392:debate [Activity]
   770   C1880177:Contribute [Activity]

Phrase: "and"

Phrase: "the prospects of development"

Phrase: "over the next 10 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439234:years [Temporal Concept]
   793 E C0439508:/year [Temporal Concept]

Phrase: "make"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1881534:Make [Functional Concept]

Phrase: "this one of the most exciting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0205447:One [Quantitative Concept]

Phrase: "and"

Phrase: "dynamic areas of medicine"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0205146:areas [Spatial Concept]
   737 E C0017446:Area [Geographic Area]

Phrase: "in which to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "work."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]
Processing 00000000.tx.133: View this table: [in this window] [in a new window]  Table 2 Current and potential treatments for dementia  Clinical Implications and Limitations CLINICAL IMPLICATIONS Anticholinesterase therapy is a major contribution to the therapeutic treatment regimen in Alzheimer's disease  as now endorsed by the National Institute for Clinical Excellence. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2 Current"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0521116:Current [Temporal Concept]
   827   C1705970:Current [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "potential treatments for dementia  Clinical Implications"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   767   C1516635:Clinical Treatment [Therapeutic or Preventive Procedure]
   753   C0087111:Treatments [Therapeutic or Preventive Procedure]
   719 E C0039798:treatment [Functional Concept]
   719 E C1522326:Treatment [Functional Concept]
   719 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   719 E C1705169:Treatment [Conceptual Entity]
   719 E C3538994:TREATMENT [Research Activity]

Phrase: "and"

Phrase: "Limitations CLINICAL IMPLICATIONS Anticholinesterase therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0039798:therapy [Functional Concept]
   804   C0087111:Therapy [Therapeutic or Preventive Procedure]
   804   C1363945:Therapy [Finding]

Phrase: "is"

Phrase: "a major contribution to the therapeutic treatment regimen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1880177:Contribution [Activity]

Phrase: "in Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "as"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "endorsed by the National Institute"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]
   760   C3245503:national [Intellectual Product]

Phrase: "for Clinical Excellence."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   789   C1548784:Excellent [Qualitative Concept]
   789   C1961136:Excellent [Qualitative Concept]
Processing 00000000.tx.134: Psychopharmacology of Alzheimer's disease is now an important addition to the old age psychiatrist's skills  and professional development requirements. 

Phrase: "Psychopharmacology of Alzheimer's disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0033929:Psychopharmacology [Biomedical Occupation or Discipline]

Phrase: "is"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "an important addition to the old age psychiatrist's skills"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1883712:Addition [Functional Concept]

Phrase: "and"

Phrase: "professional development requirements."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C1514873:Requirement [Functional Concept]
   734   C0871147:professional development [Occupational Activity]
Processing 00000000.tx.135: Services will need to move towards the diagnosis of early, mild dementia rather than intervene at the moderate to severe stages. 

Phrase: "Services"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0557854:Services [Occupational Activity]
   966 E C2825316:Service [Manufactured Object]
   966 E C3245478:service [Idea or Concept]

Phrase: "will"

Phrase: "need"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "move towards the diagnosis of early,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   783   C0596473:Early Diagnosis [Diagnostic Procedure]
   753   C0011900:Diagnosis [Finding]
   753   C0560560:move [Organism Function]
   753   C0578671:move [Finding]
   753   C1269909:move [Functional Concept]
   753   C1279919:Early [Temporal Concept]
   753   C1299988:move [Functional Concept]
   753   C1704338:diagnosis [Qualitative Concept]
   753   C1704656:DIAGNOSIS [Research Activity]
   753   C2699029:Move [Activity]

Phrase: "mild dementia"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C3494623:Mild dementia [Mental or Behavioral Dysfunction]
   861   C0011265:dementia [Mental or Behavioral Dysfunction]
   861   C0497327:Dementia [Mental or Behavioral Dysfunction]
   761 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "rather than"

Phrase: "intervene at the moderate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205081:Moderate [Qualitative Concept]
   770   C1881878:Moderate [Qualitative Concept]

Phrase: "to severe stages."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C1306673:Stages [Qualitative Concept]
   827 E C0205390:Stage [Temporal Concept]
   827 E C1300072:Stage [Clinical Attribute]
Processing 00000000.tx.136: LIMITATIONS Funding of these new drugs may be hard to obtain, especially in areas where basic service needs are unmet and require attention first. 

Phrase: "LIMITATIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449295:limitations [Functional Concept]

Phrase: "Funding of these new drugs"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0013227:Drugs [Pharmacologic Substance]
   760   C0205314:New [Temporal Concept]
   760   C0243098:Funding [Quantitative Concept]
   760   C0376244:funding [Quantitative Concept]
   726 E C0016820:Fund [Quantitative Concept]
   726 E C1254351:Drug [Pharmacologic Substance]

Phrase: "may"

Phrase: "be"

Phrase: "hard to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0018599:Hard [Qualitative Concept]

Phrase: "obtain"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C1301820:Obtain [Functional Concept]
  1000   C1706701:Obtain [Activity]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442805:Increase [Functional Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C3245488:acquired [Intellectual Product]

Phrase: ","

Phrase: "especially in areas where basic service needs"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   748   C0027552:Needs [Qualitative Concept]
   748   C0205146:areas [Spatial Concept]
   748   C0557854:Service [Occupational Activity]
   748   C0686904:needs [Functional Concept]
   748   C1527178:Basic [Functional Concept]
   748   C2825316:Service [Manufactured Object]
   748   C3245478:service [Idea or Concept]
   714 E C0017446:Area [Geographic Area]

Phrase: "are"

Phrase: "unmet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3274904:Unmet [Activity]

Phrase: "and"

Phrase: "require"

Phrase: "attention first."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205435:First [Quantitative Concept]
   861   C1279901:First [Qualitative Concept]
Processing 00000000.tx.137: These are only symptomatic treatments  we now need drugs that change the course of the illness. 

Phrase: "These"

Phrase: "are"

Phrase: "only symptomatic treatments"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   827   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827   C0231220:Symptomatic [Functional Concept]
   793 E C0039798:treatment [Functional Concept]
   793 E C1522326:Treatment [Functional Concept]
   793 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   793 E C1705169:Treatment [Conceptual Entity]
   793 E C3538994:TREATMENT [Research Activity]

Phrase: "we now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "need"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "that"

Phrase: "change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0392747:Change [Functional Concept]
  1000   C0443172:change [Quantitative Concept]
  1000   C1705241:Change [Quantitative Concept]

Phrase: "the course of the illness."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   844   C0242656:Course of illness [Pathologic Function]
           course illness
   760   C0750729:Course [Temporal Concept]
Processing 00000000.tx.138: No single therapy is likely to be the solution to Alzheimer's disease. 

Phrase: "No single therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "is"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "be"

Phrase: "the solution to Alzheimer's disease."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037633:Solution [Substance]
   760   C0525069:Solution [Biomedical or Dental Material]
Processing 00000000.tx.139: We need to learn how best to use cholinesterase inhibitors, and then how to combine them with new drugs as they arrive. 

Phrase: "We"

Phrase: "need"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "learn"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023185:learn [Mental Process]

Phrase: "how best to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1522427:Best [Qualitative Concept]

Phrase: "use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "cholinesterase inhibitors,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0008425:Cholinesterase Inhibitors [Organic Chemical,Pharmacologic Substance]
  1000   C2757012:Cholinesterase Inhibitors [Molecular Function]
   966 E C3536756:Cholinesterase Inhibitor [Pharmacologic Substance]
   861   C0008429:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0033791:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   861   C0728810:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "and"

Phrase: "then how to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1883708:Then [Temporal Concept]

Phrase: "combine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0336789:Combine [Manufactured Object]

Phrase: "them with new drugs"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0013227:Drugs [Pharmacologic Substance]
   770   C0205314:New [Temporal Concept]
   737 E C1254351:Drug [Pharmacologic Substance]

Phrase: "as"

Phrase: "they"

Phrase: "arrive."
Processing 00000000.tx.140: It will be a while before this can be initiated at the level of primary care. 

Phrase: "It"

Phrase: "will"

Phrase: "be"

Phrase: "a"

Phrase: "while"

Phrase: "before"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332152:Before [Temporal Concept]
  1000   C1705850:Before [Intellectual Product]

Phrase: "this"

Phrase: "can"

Phrase: "be"

Phrase: "initiated at the level of primary care."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   804   C1547668:Level of Care [Idea or Concept]
   804   C1548572:Level of care [Intellectual Product]
   778   C0033137:Primary Care [Health Care Activity]
   748   C0205225:Primary [Qualitative Concept]
   748   C0439631:Primary [Therapeutic or Preventive Procedure]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C1947933:Care [Activity]
   748   C2946261:Level [Pharmacologic Substance]
   714   C1548602:Initiate [Idea or Concept]
   714   C1704686:Initiate [Functional Concept]
Processing 00000000.tx.141: ACKNOWLEDGMENTS The author thanks colleagues who have used these drugs to date for their participation in various consensus groups in order to fill in the gaps in this review where evidence remains weak. 

Phrase: "ACKNOWLEDGMENTS"

Phrase: "The author"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221193:Author [Professional or Occupational Group]

Phrase: "thanks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "colleagues"

Phrase: "who"

Phrase: "have"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "these drugs to date"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0013227:Drugs [Pharmacologic Substance]
   737 E C1254351:Drug [Pharmacologic Substance]

Phrase: "for their participation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0679823:Participation [Functional Concept]

Phrase: "in various consensus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0376298:Consensus [Social Behavior]

Phrase: "groups in order"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   790   C0441833:Group [Idea or Concept]
   790   C0687744:group [Population Group]
   790   C1257890:Group [Population Group]
   790   C1552516:Group [Health Care Related Organization]
   790   C1552839:groups [Idea or Concept]
   790   C1705175:Order [Intellectual Product]
   790   C1705176:Order [Qualitative Concept]
   790   C1705177:Order [Classification]
   790   C1705178:Order [Activity]
   790   C1705428:Group [Conceptual Entity]
   790   C1705429:Group [Population Group]
   790   C1882348:Order [Qualitative Concept]

Phrase: "to fill in"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3273494:Fill In [Activity]
   861   C1708059:Fill [Activity]

Phrase: "the gaps in this review where evidence"

Phrase: "remains"

Phrase: "weak."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0004093:Weak [Sign or Symptom]
  1000   C1762617:Weak [Qualitative Concept]
Processing 00000000.tx.142: REFERENCES Arendt, T. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Arendt,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.143: (1992) Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development; 

Phrase: "(1992"

Phrase: ")"

Phrase: "Changes in acetylcholinesterase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0001044:Acetylcholine esterase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0392747:Change [Functional Concept]
   790   C0443172:change [Quantitative Concept]
   790   C1705241:Change [Quantitative Concept]

Phrase: "and"

Phrase: "butyrylcholinesterase in Alzheimer's disease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0728810:Butyrylcholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C1412756:BUTYRYLCHOLINESTERASE [Gene or Genome]

Phrase: "resemble"

Phrase: "embryonic development"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013936:Embryonic Development [Organ or Tissue Function]
  1000   C0243100:embryonic development [Functional Concept]
   861   C0243107:development [Physiologic Function]
   861   C0678723:Development [Organism Function]
   861   C1527148:Development [Functional Concept]
   789 E C0458003:Developmental [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.144: a study of molecular forms. 

Phrase: "a study of molecular forms."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]
Processing 00000000.tx.145: Neurochemistry International, 21, 381-396.[Medline] Birge, S. 

Phrase: "Neurochemistry International, 21,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0027820:Neurochemistry [Biomedical Occupation or Discipline]
   827   C0699841:neurochemistry [Organ or Tissue Function]
   827   C1512888:International [Idea or Concept]

Phrase: "381-396."

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Birge,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.146: J. 

Phrase: "J."
Processing 00000000.tx.147: (1997) The role of oestrogen in the treatment of Alzheimer's disease. 

Phrase: "(1997"

Phrase: ")"

Phrase: "The role of oestrogen"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "in the treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "of Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.148: Neurology, 48 (suppl. 5), 36-40. 

Phrase: "Neurology,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0027855:Neurology [Biomedical Occupation or Discipline]
   928 E C0205494:Neurologic [Qualitative Concept]
   928 E C2707261:Neurological [Clinical Attribute]
   907 E C0027763:Nervous System [Body System]
   907 E C0422837:NERVOUS SYSTEM [Finding]
   907 E C1269560:Nervous system [Body System]

Phrase: "48"

Phrase: "(suppl. 5"

Phrase: ")"

Phrase: ","

Phrase: "36-40."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439509:/40 [Temporal Concept]
Processing 00000000.tx.149: Bullock, R. 

Phrase: "Bullock,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.150: (1998) Drug treatment for early Alzheimer's disease. 

Phrase: "(1998"

Phrase: ")"

Phrase: "Drug treatment for early Alzheimer's disease."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   820   C1979617:Alzheimer's disease treatment [Therapeutic or Preventive Procedure]
   753   C0013227:Drug [Pharmacologic Substance]
   753   C0039798:treatment [Functional Concept]
   753   C0087111:Treatment [Therapeutic or Preventive Procedure]
   753   C1254351:Drug [Pharmacologic Substance]
   753   C1522326:Treatment [Functional Concept]
   753   C1533734:Treatment [Therapeutic or Preventive Procedure]
   753   C1705169:Treatment [Conceptual Entity]
   753   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.151: Advances in Psychiatric Treatment, 4, 126-134. 

Phrase: "Advances in Psychiatric Treatment,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C0725066:Advance [Medical Device]

Phrase: "4,"

Phrase: "126-134."
Processing 00000000.tx.152: Cameron, I., Curran, S., Newton, P., et al (2000) Use of donepezil for the treatment of mildmoderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice. 

Phrase: "Cameron,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Curran,"

Phrase: "S."

Phrase: ","

Phrase: "Newton,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0542569:newton [Quantitative Concept]

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Use of donepezil"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   882   C1524063:Use of [Functional Concept]
   790   C0042153:use [Functional Concept]
   790   C0457083:Use [Functional Concept]
   790   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]
   790   C1947944:Use [Intellectual Product]

Phrase: "for the treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "of mildmoderate Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0002395:Alzheimer's Disease [Disease or Syndrome]
   901   C1521724:Alzheimer's Disease [Pathologic Function]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: ":"

Phrase: "an audit of the assessment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1704774:Audit [Conceptual Entity]
   760   C1704775:Audit [Functional Concept]

Phrase: "and"

Phrase: "treatment of patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "in routine clinical practice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0237607:practice [Mental Process]
   827   C3245512:practice [Intellectual Product]
Processing 00000000.tx.153: International Journal of Geriatric Psychiatry, 15, 887-891.[CrossRef][Medline] Corey-Bloom, J., Anand, R., Veach, J., for the ENA 713 E352 study group (1998) A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "15,"

Phrase: "887-891."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Corey-Bloom,"

Phrase: "J.,"

Phrase: "Anand,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Veach,"

Phrase: "J.,"

Phrase: "for the ENA 713 E352 study group"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   804   C0441833:Group [Idea or Concept]
   804   C0557651:Study [Manufactured Object]
   804   C0687744:group [Population Group]
   804   C1257890:Group [Population Group]
   804   C1552516:Group [Health Care Related Organization]
   804   C1705428:Group [Conceptual Entity]
   804   C1705429:Group [Population Group]
   804   C2603343:Study [Research Activity]

Phrase: "(1998"

Phrase: ")"

Phrase: "A randomised trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008976:Trial [Research Activity]

Phrase: "evaluating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0220825:Evaluate [Functional Concept]

Phrase: "the efficacy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280519:Efficacy [Qualitative Concept]
  1000   C1707887:EFFICACY [Research Activity]

Phrase: "and"

Phrase: "safety of ENA 713"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0036043:Safety [Human-caused Phenomenon or Process]
   770   C1705187:SAFETY [Research Activity]

Phrase: "(rivastigmine tartrate"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0772415:Rivastigmine tartrate [Organic Chemical,Pharmacologic Substance]
   861   C0039328:tartrate [Carbohydrate]
   861   C0144544:tartrate [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "a new acetylcholinesterase inhibitor,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0001046:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   901   C3536756:Acetylcholinesterase Inhibitor [Pharmacologic Substance]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with mild to moderately severe Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0002395:Alzheimer's Disease [Disease or Syndrome]
   827   C1521724:Alzheimer's Disease [Pathologic Function]
   799   C0012634:Disease [Disease or Syndrome]
   743 E C1836721:MALS [Finding]
   743 E C3538764:MALS [Gene or Genome]
   743 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.154: International Journal of Geriatric Psychopharmacology, 1, 55-65. 

Phrase: "International Journal of Geriatric Psychopharmacology,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "55-65."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450382:55 [Intellectual Product]
   861   C0450385:65 [Intellectual Product]
Processing 00000000.tx.155: Cummings, J. 

Phrase: "Cummings,"

Phrase: "J."
Processing 00000000.tx.156: L., Cyrus, P. 

Phrase: "L., Cyrus,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.157: A., Bieber, F., et al (1998) Metrifonate treatment of the cognitive deficits of Alzheimer's Disease. 

Phrase: "A.,"

Phrase: "Bieber,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "et al (1998"

Phrase: ")"

Phrase: "Metrifonate treatment of the cognitive deficits of Alzheimer's Disease."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   784   C1979617:Alzheimer's disease treatment [Therapeutic or Preventive Procedure]
   742   C0039798:treatment [Functional Concept]
   742   C0087111:Treatment [Therapeutic or Preventive Procedure]
   742   C1522326:Treatment [Functional Concept]
   742   C1533734:Treatment [Therapeutic or Preventive Procedure]
   742   C1705169:Treatment [Conceptual Entity]
   742   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.158: Metrifonate study group. 

Phrase: "Metrifonate study group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   827   C0441833:Group [Idea or Concept]
   827   C0557651:Study [Manufactured Object]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   827   C2603343:Study [Research Activity]
Processing 00000000.tx.159: Neurology, 50, 1214-1221.[Abstract] Davies, P. 

Phrase: "Neurology,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0027855:Neurology [Biomedical Occupation or Discipline]
   928 E C0205494:Neurologic [Qualitative Concept]
   928 E C2707261:Neurological [Clinical Attribute]
   907 E C0027763:Nervous System [Body System]
   907 E C0422837:NERVOUS SYSTEM [Finding]
   907 E C1269560:Nervous system [Body System]

Phrase: "50,"

Phrase: "1214-1221."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Davies,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.160: & Maloney, A. 

Phrase: "& Maloney,"

Phrase: "A."
Processing 00000000.tx.161: J. 

Phrase: "J."
Processing 00000000.tx.162: F. 

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.163: (1976) Selective loss of central cholinergic neurones in Alzheimer's disease. 

Phrase: "(1976"

Phrase: ")"

Phrase: "Selective loss of central cholinergic neurones"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   785   C0598940:Loss of neurons [Finding]
   753   C1517945:Loss [Quantitative Concept]
   742   C1850496:Neuronal loss [Finding]

Phrase: "in Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.164: Lancet, ii, 1403. 

Phrase: "Lancet,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0777169:Lancet [Medical Device]

Phrase: "ii,"

Phrase: "1403."
Processing 00000000.tx.165: Evans, M., Ellis, A., Watson, D., et al (2000) Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. 

Phrase: "Evans,"

Phrase: "M."

Phrase: ","

Phrase: "Ellis,"

Phrase: "A.,"

Phrase: "Watson,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3476816:Watson [Quantitative Concept]

Phrase: "D."

Phrase: ","

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Sustained"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0443318:Sustained [Functional Concept]
   966 E C2732140:Sustain [Organic Chemical,Pharmacologic Substance]

Phrase: "cognitive improvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986411:Improvement [Conceptual Entity]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "treatment of Alzheimer's disease"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   881   C1979617:Alzheimer's disease treatment [Therapeutic or Preventive Procedure]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "with donepezil."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.166: International Journal of Geriatric Psychiatry, 15, 50-53.[CrossRef][Medline] Folstein, M. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "15,"

Phrase: "50-53."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Folstein,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.167: F., Folstein, S. 

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Folstein,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.168: E. 

Phrase: "E."
Processing 00000000.tx.169: & McHugh, P. 

Phrase: "& McHugh,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.170: R. 

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.171: (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. 

Phrase: "(1975"

Phrase: ")"

Phrase: "Mini-Mental State"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
   901   C0278060:Mental state [Finding]
   827   C0229992:mental [Mental Process]
   827   C1301808:State [Geographic Area]
   827   C1442792:State [Functional Concept]
   827   C3148680:State [Geographic Area]
   743 E C0229993:Psychic [Functional Concept]
   727 E C0011980:Diaphragm [Body Part, Organ, or Organ Component]
   727 E C0042241:DIAPHRAGM [Medical Device]
   727 E C1279038:Diaphragm [Body Part, Organ, or Organ Component]
   727 E C1705367:Diaphragm [Medical Device]
   716 E C0086045:mindfulness [Mental Process]
   716 E C3542996:Mindfulness [Mental Process]

Phrase: ":"

Phrase: "a practical method for grading"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0025663:Method [Intellectual Product]
   760   C0449851:Method [Functional Concept]
   760   C0871511:METHOD [Intellectual Product]

Phrase: "the cognitive state of patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   781   C0683521:Patient State [Finding]
   760   C1301808:State [Geographic Area]
   760   C1442792:State [Functional Concept]
   760   C1516691:Cognitive [Functional Concept]
   760   C3148680:State [Geographic Area]

Phrase: "for the clinician."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0871685:Clinician [Professional or Occupational Group]
  1000   C1550470:clinician [Idea or Concept]
Processing 00000000.tx.172: Journal of Psychiatric Research, 12, 189-198.[CrossRef][Medline] Harvey, R. 

Phrase: "Journal of Psychiatric Research,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "12,"

Phrase: "189-198."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Harvey,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.173: J. 

Phrase: "J."
Processing 00000000.tx.174: (1999) A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. 

Phrase: "(1999"

Phrase: ")"

Phrase: "A review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: "and"

Phrase: "commentary on a sample of 15 UK guidelines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0282411:Commentary [Intellectual Product]

Phrase: "for the drug treatment"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   861   C0013227:Drug [Pharmacologic Substance]
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1254351:Drug [Pharmacologic Substance]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "of Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.175: International Journal of Geriatric Psychiatry, 14, 249-256.[CrossRef][Medline] Livingston, G. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "14,"

Phrase: "249-256."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Livingston,"

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.176: & Katona, C. 

Phrase: "& Katona,"

Phrase: "C."
Processing 00000000.tx.177: (2000) How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? 

Phrase: "(2000"

Phrase: ")"

Phrase: "How useful"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   789   C0042153:use [Functional Concept]
   789   C0457083:Use [Functional Concept]
   789   C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "cholinesterase inhibitors in the treatment of Alzheimer's disease?"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   770   C0008425:Cholinesterase Inhibitors [Organic Chemical,Pharmacologic Substance]
   770   C2757012:Cholinesterase Inhibitors [Molecular Function]
   744   C0008429:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0033791:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0243077:inhibitors [Chemical Viewed Functionally]
   744   C0728810:Cholinesterase [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C3536756:Cholinesterase Inhibitor [Pharmacologic Substance]
   711 E C1999216:Inhibitor [Qualitative Concept]
Processing 00000000.tx.178: A number needed to treat analysis. 

Phrase: "A number"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237753:*Number [Quantitative Concept]
  1000   C0449788:Number [Quantitative Concept]

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "analysis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002778:Analysis [Laboratory Procedure]
  1000   C0936012:Analysis [Research Activity]
  1000   C1524024:analysis [Functional Concept]
Processing 00000000.tx.179: International Journal of Geriatric Psychiatry, 15, 203-207.[CrossRef][Medline] Matthews, H. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "15,"

Phrase: "203-207."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Matthews,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.180: P., Korbey, J., Wilkinson, D. 

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Korbey,"

Phrase: "J.,"

Phrase: "Wilkinson,"

Phrase: "D."
Processing 00000000.tx.181: G., et al (2000) Donepezil in Alzheimer's disease: eighteen-month results from Southampton Memory Clinic. 

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Donepezil in Alzheimer's disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0527316:donepezil [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "eighteen-month"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "results from Southampton Memory Clinic."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   760   C0002424:Clinic [Health Care Related Organization,Manufactured Object]
   760   C0025260:Memory [Mental Process]
   760   C0442592:Clinic [Health Care Related Organization,Manufactured Object]
   760   C0700327:memory [Finding]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C1706377:Memory [Manufactured Object]
   760   C2825142:Result [Finding]
   704 E C0679055:mnemonic [Mental Process]
Processing 00000000.tx.182: International Journal of Geriatric Psychiatry, 15, 713-720.[CrossRef][Medline] McGeer, P. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "15,"

Phrase: "713-720."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] McGeer,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.183: L. 

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.184: & McGeer, E. 

Phrase: "& McGeer,"

Phrase: "E."
Processing 00000000.tx.185: G. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.186: (1998) Mechanisms of cell death in Alzheimer's disease  immunopathology. 

Phrase: "(1998"

Phrase: ")"

Phrase: "Mechanisms of cell death"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   988   C1708951:Mechanism of Cell Death [Cell Function]
   770   C0441712:Mechanisms [Functional Concept]
   737 E C1706376:Mechanism [Manufactured Object]

Phrase: "in Alzheimer's disease  immunopathology."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0596756:Immunopathology [Biomedical Occupation or Discipline]
   827   C1555821:Immunopathology [Intellectual Product]
   827   C1609432:Immunopathology [Disease or Syndrome]
   734   C0002395:Alzheimer's Disease [Disease or Syndrome]
   734   C1521724:Alzheimer's Disease [Pathologic Function]
Processing 00000000.tx.187: Journal of Neuronal Transmission, 54 (suppl.), 159-166. 

Phrase: "Journal of Neuronal Transmission,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "54"

Phrase: "(suppl."

Phrase: ")"

Phrase: ","

Phrase: "159-166."
Processing 00000000.tx.188: McKeith, I., Grace, J., Walker, Z., et al (2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. 

Phrase: "McKeith,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Grace,"

Phrase: "J.,"

Phrase: "Walker,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043016:Walker [Medical Device]

Phrase: "Z.,"

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Rivastigmine in the treatment of dementia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "with Lewy bodies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0085200:Lewy Bodies [Cell Component]
   861   C0242821:bodies [Human]
   861   C1995017:Bodies [Cell Component]
   827 E C0460148:Body [Anatomical Structure]
   827 E C1268086:Body [Anatomical Structure]

Phrase: ":"

Phrase: "preliminary findings from an open trial."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   753   C2607943:findings [Functional Concept]
   753   C2926606:Findings [Clinical Attribute]
   753   C3539655:Findings [Intellectual Product]
   719 E C0037088:Finding [Sign or Symptom]
   719 E C0243095:Finding [Finding]
   719 E C2825141:Finding [Finding]
Processing 00000000.tx.189: International Journal of Geriatric Psychiatry, 15, 387-392.[CrossRef][Medline] Mulnard, R. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "15,"

Phrase: "387-392."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Mulnard,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.190: A., Cotman, C. 

Phrase: "A.,"

Phrase: "Cotman,"

Phrase: "C."
Processing 00000000.tx.191: W., Kawas, C., et al (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. 

Phrase: "W., Kawas,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0521083:Kawas [Plant]

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease."
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   775   C0014935:Estrogen Replacement Therapy [Therapeutic or Preventive Procedure]
           Estrogen Replacement
   756   C0086258:Estrogen Replacement [Therapeutic or Preventive Procedure]
   756   C0279033:Replacement therapy [Therapeutic or Preventive Procedure]
   754   C0279494:estrogen therapy [Therapeutic or Preventive Procedure]
   738   C0014939:Estrogen [Hormone,Pharmacologic Substance,Steroid]
   738   C0035139:Replacement [Therapeutic or Preventive Procedure]
   738   C0039798:therapy [Functional Concept]
   738   C0087111:Therapy [Therapeutic or Preventive Procedure]
   738   C0559956:Replacement [Functional Concept]
   738   C1363945:Therapy [Finding]
   738   C1555302:Replacement [Idea or Concept]
   738   C2936882:Estrogen [Pharmacologic Substance]
Processing 00000000.tx.192: JAMA, 283, 1007-1015.[Abstract/Free FullText] National Institute for Clinical Excellence (2001) Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. 

Phrase: "JAMA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1422839:JAMA [Gene or Genome]

Phrase: "283,"

Phrase: "1007-1015."

Phrase: "[Abstract/Free FullText"

Phrase: "] National Institute for Clinical Excellence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]

Phrase: "(2001"

Phrase: ")"

Phrase: "Guidance on the Use of Donepezil,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0150600:Guidance [Health Care Activity]
   753   C1959633:Guidance [Clinical Attribute]

Phrase: "Rivastigmine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0649350:rivastigmine [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "Galantamine for the Treatment of Alzheimer's Disease."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.193: London: NICE. 

Phrase: "London"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023973:London [Geographic Area]

Phrase: ":"

Phrase: "NICE."
Processing 00000000.tx.194: Raskind, M. 

Phrase: "Raskind,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.195: A., Peskind, E. 

Phrase: "A.,"

Phrase: "Peskind,"

Phrase: "E."
Processing 00000000.tx.196: R., Wessel, T., et al (2000) Galantamine in AD: a 6-month randomized placebo controlled trial with a 6-month extension. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Wessel,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "et al (2000"

Phrase: ")"

Phrase: "Galantamine in AD"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0016967:Galantamine [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "a 6-month"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "placebo controlled trial with a 6-month extension."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0008976:Trial [Research Activity]
Processing 00000000.tx.197: Neurology, 54, 2261-2268.[Abstract/Free FullText] Robinson, D., Friedman, L., Marcus, R., et al (1994) Estrogen replacement therapy and memory in older women. 

Phrase: "Neurology,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0027855:Neurology [Biomedical Occupation or Discipline]
   928 E C0205494:Neurologic [Qualitative Concept]
   928 E C2707261:Neurological [Clinical Attribute]
   907 E C0027763:Nervous System [Body System]
   907 E C0422837:NERVOUS SYSTEM [Finding]
   907 E C1269560:Nervous system [Body System]

Phrase: "54,"

Phrase: "2261-2268."

Phrase: "[Abstract/Free FullText"

Phrase: "] Robinson,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443050:Robinson [Intellectual Product]

Phrase: "D."

Phrase: ","

Phrase: "Friedman,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Marcus,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "et al (1994"

Phrase: ")"

Phrase: "Estrogen replacement therapy"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
  1000   C0014935:Estrogen Replacement Therapy [Therapeutic or Preventive Procedure]
           Estrogen Replacement
   913   C0279494:estrogen therapy [Therapeutic or Preventive Procedure]
   901   C0086258:Estrogen Replacement [Therapeutic or Preventive Procedure]
   901   C0279033:Replacement therapy [Therapeutic or Preventive Procedure]
   827   C0014939:Estrogen [Hormone,Pharmacologic Substance,Steroid]
   827   C0035139:Replacement [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C0559956:Replacement [Functional Concept]
   827   C1363945:Therapy [Finding]
   827   C1555302:Replacement [Idea or Concept]
   827   C2936882:Estrogen [Pharmacologic Substance]
   755 E C0720298:Estrogenic [Hormone,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "memory in older women."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0025260:Memory [Mental Process]
   770   C0700327:memory [Finding]
   770   C1706377:Memory [Manufactured Object]
   715 E C0679055:mnemonic [Mental Process]
Processing 00000000.tx.198: Journal of the American Geriatric Society, 42, 919-922. 

Phrase: "Journal of the American Geriatric Society,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "42,"

Phrase: "919-922."
Processing 00000000.tx.199: Rogers, S. 

Phrase: "Rogers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C3463939:Roger [Eukaryote]

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.200: L., Farlow, M. 

Phrase: "L., Farlow,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.201: R., Doody, R. 

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Doody,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.202: S., et al (1998) A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. 

Phrase: "S."

Phrase: ","

Phrase: "et al (1998"

Phrase: ")"

Phrase: "A 24-week,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332174:/week [Temporal Concept]
   861   C0439230:week [Temporal Concept]

Phrase: "double blind,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0013072:DOUBLE BLIND [Research Activity]
   861   C0150108:Blind [Research Activity]
   861   C0205173:Double [Functional Concept]
   861   C0456909:Blind [Disease or Syndrome]
   861   C0525065:blind [Patient or Disabled Group]
   861   C1705764:Double [Activity]
   861   C1705765:Double [Qualitative Concept]

Phrase: "placebo-controlled trial of donepezil"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0008976:Trial [Research Activity]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with Alzheimer's disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.203: Neurology, 50, 136-145.[Abstract] Sano, M., Ernesto, C., Thomas, R. 

Phrase: "Neurology,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0027855:Neurology [Biomedical Occupation or Discipline]
   928 E C0205494:Neurologic [Qualitative Concept]
   928 E C2707261:Neurological [Clinical Attribute]
   907 E C0027763:Nervous System [Body System]
   907 E C0422837:NERVOUS SYSTEM [Finding]
   907 E C1269560:Nervous system [Body System]

Phrase: "50,"

Phrase: "136-145."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Sano,"

Phrase: "M."

Phrase: ","

Phrase: "Ernesto,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Thomas,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.204: C., et al (1997) A controlled trial of selegiline, alpha tocopherol, or both, as treatment for Alzheimer's disease. 

Phrase: "C., et al (1997"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1553033:[c] [Quantitative Concept]

Phrase: ")"

Phrase: "A controlled trial of selegiline,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0008976:Trial [Research Activity]

Phrase: "alpha tocopherol,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0969677:.ALPHA.-Tocopherol [Lipid,Organic Chemical,Pharmacologic Substance,Vitamin]
  1000   C1142098:Alpha Tocopherol [Laboratory Procedure]
   861   C0087096:Tocopherol [Lipid,Pharmacologic Substance,Vitamin]
   861   C0439095:Alpha [Intellectual Product]
   861   C2003941:Alpha [Intellectual Product]
   861   C2350010:Alpha [Qualitative Concept]
   861   C3255108:Tocopherol [Pharmacologic Substance]

Phrase: "or"

Phrase: "both,"

Phrase: "as"

Phrase: "treatment for Alzheimer's disease."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   881   C1979617:Alzheimer's disease treatment [Therapeutic or Preventive Procedure]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.205: New England Journal of Medicine, 336, 1216-1222.[Abstract/Free FullText] Schenk, D., Barber, R., Dunn, W., et al (1999) Immunisation with -amyloid attenuates Alzheimer disease like pathology in the PDAPP mouse. 

Phrase: "New England Journal of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "336,"

Phrase: "1216-1222."

Phrase: "[Abstract/Free FullText"

Phrase: "] Schenk,"

Phrase: "D."

Phrase: ","

Phrase: "Barber,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0335371:Barber [Professional or Occupational Group]

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Dunn,"

Phrase: "W.,"

Phrase: "et al (1999"

Phrase: ")"

Phrase: "Immunisation with -amyloid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   790   C0042196:immunisation [Therapeutic or Preventive Procedure]
   790   C3244291:immunization [Functional Concept]

Phrase: "attenuates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0599946:Attenuate [Activity]

Phrase: "Alzheimer disease like pathology"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   770   C0012634:Disease [Disease or Syndrome]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "in the PDAPP mouse."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mouse [Mammal]
   861   C0025929:mouse [Mammal]
   861   C0026809:Mouse [Mammal]
Processing 00000000.tx.206: Nature, 400, 173-177.[CrossRef][Medline] Schneider, L. 

Phrase: "Nature,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0349590:Nature [Idea or Concept]
  1000   C1262865:Nature [Functional Concept]
   928 E C0205296:Natural [Functional Concept]

Phrase: "400,"

Phrase: "173-177."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Schneider,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.207: S. 

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.208: & Farlow, M. 

Phrase: "& Farlow,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.209: R. 

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.210: (1995) Predicting response to cholinesterase inhibitors in Alzheimer's disease: possible approaches. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Predicting response to cholinesterase inhibitors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "in Alzheimer's disease"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: ":"

Phrase: "possible approaches."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449445:Approaches [Spatial Concept]
   861   C1292724:Approaches [Functional Concept]
Processing 00000000.tx.211: CNS Drugs, 4, 114-124. 

Phrase: "CNS Drugs,"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0007680:CNS DRUGS [Pharmacologic Substance]
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "4,"

Phrase: "114-124."
Processing 00000000.tx.212: Stewart, W. 

Phrase: "Stewart,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551641:Stewart [Population Group]

Phrase: "W."
Processing 00000000.tx.213: F., Kawas, C., Corrada, M., et al (1997) Risk of Alzheimer's disease and duration of NSAID use. 

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Kawas,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521083:Kawas [Plant]

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Corrada,"

Phrase: "M."

Phrase: ","

Phrase: "et al (1997"

Phrase: ")"

Phrase: "Risk of Alzheimer's disease"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   833   C0002395:Alzheimer's Disease [Disease or Syndrome]
   833   C1521724:Alzheimer's Disease [Pathologic Function]
   819   C1281905:disease risk [Finding]
   770   C0012634:Disease [Disease or Syndrome]
   770   C0035647:Risk [Qualitative Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "duration of NSAID use."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   881   C1881378:DURATION OF USE [Functional Concept]
   881   C2826775:Duration of Use [Temporal Concept]
   770   C0449238:Duration [Temporal Concept]
   770   C2926735:Duration [Pharmacologic Substance]
Processing 00000000.tx.214: Neurology, 48, 626-632.[Abstract] Winblad, B. 

Phrase: "Neurology,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0027855:Neurology [Biomedical Occupation or Discipline]
   928 E C0205494:Neurologic [Qualitative Concept]
   928 E C2707261:Neurological [Clinical Attribute]
   907 E C0027763:Nervous System [Body System]
   907 E C0422837:NERVOUS SYSTEM [Finding]
   907 E C1269560:Nervous system [Body System]

Phrase: "48,"

Phrase: "626-632."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Winblad,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.215: & Poritis, N. 

Phrase: "& Poritis,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.216: (1999) Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). 

Phrase: "(1999"

Phrase: ")"

Phrase: "Memantine in severe dementia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0025242:Memantine [Organic Chemical,Pharmacologic Substance]

Phrase: ":"

Phrase: "results of the"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   756   C1274040:Result [Functional Concept]
   756   C1546471:Result [Idea or Concept]
   756   C2825142:Result [Finding]

Phrase: "M-"

Phrase: "BEST Study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "(benefit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0814225:Benefit [Quantitative Concept]

Phrase: "and"

Phrase: "efficacy in severely demented patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280519:Efficacy [Qualitative Concept]
   760   C1707887:EFFICACY [Research Activity]

Phrase: "during treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with memantine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025242:Memantine [Organic Chemical,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.217: International Journal of Geriatric Psychiatry, 14, 135-146.[CrossRef][Medline] Received for publication April 20, 2000. 

Phrase: "International Journal of Geriatric Psychiatry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162443:Journal [Intellectual Product,Manufactured Object]

Phrase: "14,"

Phrase: "135-146."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "Received for publication April 20,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0034036:Publication [Intellectual Product,Manufactured Object]
   760   C0034037:Publication [Occupational Activity]
   760   C1514756:Received [Qualitative Concept]
   760   C1704324:Publication [Intellectual Product]

Phrase: "2000."
Processing 00000000.tx.218: Revision received May 29, 2000. 

Phrase: "Revision"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439617:Revision [Temporal Concept]
  1000   C0558347:Revision [Therapeutic or Preventive Procedure]
  1000   C1527075:Revision [Therapeutic or Preventive Procedure]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "May 29,"

Phrase: "2000."
Processing 00000000.tx.219: Accepted for publication June 8, 2001. 

Phrase: "Accepted for publication June 8,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0034036:Publication [Intellectual Product,Manufactured Object]
   760   C0034037:Publication [Occupational Activity]
   760   C1272684:Accepted [Qualitative Concept]
   760   C1548435:Accepted [Idea or Concept]
   760   C1704324:Publication [Intellectual Product]
   726 E C1548601:Accept [Idea or Concept]

Phrase: "2001."
Processing 00000000.tx.220: Related articles in BJP: Highlights of this issue ELIZABETH WALSH BJP 2002 180: 0. 

Phrase: "Related articles in BJP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1706852:Article [Intellectual Product]

Phrase: ":"

Phrase: "Highlights of this issue ELIZABETH WALSH BJP 2002 180"

Phrase: ":"

Phrase: "0."
Processing 00000000.tx.221: [Full Text]  Old age psychiatry ALISTAIR BURNS and IAN G. 

Phrase: "[Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1527021:Text [Intellectual Product]
   861   C1554111:Text [Idea or Concept]
   861   C1705606:Text [Intellectual Product]
   861   C3541382:Text [Intellectual Product]

Phrase: "]  Old age psychiatry ALISTAIR BURNS"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0006434:Burns [Injury or Poisoning]
   771 E C1550619:Burn [Substance]
   717   C1273857:Old age psychiatry [Biomedical Occupation or Discipline]

Phrase: "and"

Phrase: "IAN G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.222: McKEITH BJP 2002 180: 97-98. 

Phrase: "McKEITH BJP 2002 180"

Phrase: ":"

Phrase: "97-98."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439073:97 [Intellectual Product]
   861   C0439082:>97 [Quantitative Concept]
Processing 00000000.tx.223: [Full Text]

Phrase: "[Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1527021:Text [Intellectual Product]
   861   C1554111:Text [Idea or Concept]
   861   C1705606:Text [Intellectual Product]
   861   C3541382:Text [Intellectual Product]

Phrase: "]"

